

CURRICULUM VITAE

PERSONAL PARTICULARS

Lee Ho Fun Victor
 Clinical Associate Professor
 Department of Clinical Oncology
 Li Ka Shing Faculty of Medicine
 The University of Hong Kong
 E-mail address: vhflee@hku.hk

RESEARCH INTERESTS

Nasopharyngeal cancer, Head and Neck Cancer, Lung Cancer, Liver Cancer, Novel Radiation Therapy Techniques

PROFESSIONAL QUALIFICATIONS

2015	Doctor of Medicine (MD), The University of Hong Kong
2010	Fellow of the Hong Kong Academy of Medicine (Radiology)
2010	Fellow of the Hong Kong College of Radiologists
2007	Fellow of the Royal College of Radiologists
2002	Bachelor of medicine & Bachelor of surgery, University of Hong Kong

POSTS HELD IN LI KA SHING FACULTY OF MEDICINE, THE UNIVERSITY OF HONG KONG

2009 till now	MBBS Year 3 Junior Clerkship Block C Departmental Coordinator
2010 till now	Departmental Safety Representative for Faculty Health and Safety Committee
2010 till now	Member of the Faculty-based Crisis Management Team
2010 – 2012	MBBS Year 3 Deputy Assessment Coordinator
2012 till now	MBBS Year 3 Junior Clerkship Block C Deputy Coordinator
2012 till now	Member of the Institute of Medical and Health Sciences Education (IMHSE)
2010 till now	Member of the Task Force on Head and Neck Block Planning Group
2010 till now	Member of the Task Force on Mechanisms of Disease Block Planning Group
2013 till now	Organising committee member, Hong Kong International Cancer Congress
2014 till now	MBBS year 3 (6-year) Deputy Assessment Coordinator (Written and OSCA).
2014 till now	MBBS IV and V (5-year) and IV and V (6-year) Senior Clerkship Block C Departmental Coordinator (5-year curriculum)
2014 till now	Departmental representative of MBBS III Endocrine System Block Planning Group

PART-TIME APPOINTMENT IN OTHER ACADEMIC INSTITUTION

2013 Visiting Lecturer (Part-time) in Department of Health Technology and Informatics, The Hong Kong Polytechnic University

POSTS HELD IN LOCAL AND OVERSEAS ORGANIZATIONS

2010 till now	Member, Central Committee (genetic services), Hospital Authority, Hong Kong
2010 till now	Honorary consultant, Kin Lok Club
2010 – 2012	Honorary secretary, Hong Kong Head and Neck Society
2012 till now	Member of Education and Research Fund Subcommittee, Hong Kong College of Radiologists
2012 – 2013	President-elect, Hong Kong Head and Neck Society
2013 – 2014	President, Hong Kong Head and Neck Society
2012 till now	Council Member (2012 till now), Hong Kong Nasopharyngeal Cancer Study Group
2014 till now	Member, Education Subcommittee, Hong Kong Anti-Cancer Society
2015 till now	Council Member, Hong Kong College of Radiologists
2015 till now	Member of Constitution Sub-committee, Hong Kong College of Radiologists
2017 till now	Member of the Radiation Board, Hong Kong Special Administrative Region Government

OVERSEAS TRAINING

Oct – Nov 2017	Department of Radiation Oncology, Jewish General Hospital, McGill University, Montreal, Canada
May – July 2015	Department of Oncology, Addenbrooke's Hospital, Cambridge, The United Kingdom
Aug – Sep 2013	Department of Radiation Oncology, Princess Margaret Hospital, Toronto, Canada
Apr – May 2011	Department of Radiation Oncology, Stanford University, USA
June – Aug 2010	Department of Radiation Oncology, Groupe Hospitalier Pitié-Salpêtrière, Paris, France
June – Aug 2010	Department of Radiation Oncology, Institut Gustave Roussy, Villejuif, France
June – Aug 2010	Centre Oscar Lambret, Centre Regional de Lutte contre le Cancer, Liile, France
June – Aug 2010	Centre Alexis-Vautrin, Centre Regional de Lutte contre le Cancer de Lorraine, Nancy, France

WORKING EXPERIENCE

June 2017 till now	Clinical Associate Professor, Department of Clinical Oncology, Queen Mary Hospital, The University of Hong Kong
April 2013 till now	Consultant, Clinical Oncology Center, HKU-Shenzhen Hospital, Shenzhen, People's Republic of China
May 2008 – May 2017	Clinical Assistant Professor, Department of Clinical Oncology, Queen Mary Hospital, the University of Hong Kong
Mar – Apr 2007	Elective training at Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong
Oct – Dec 2004	Elective training at Department of Diagnostic Radiology, Tuen Mun Hospital, Hong Kong
Jul 2003 – Apr 2008	Resident, Department of clinical oncology, Tuen Mun Hospital, Hong Kong
Apr – Jun 2003	House officer, Department of obstetrics & gynaecology, Queen Mary Hospital
Jan – Mar 2003	House officer, Department of paediatrics, Queen Elizabeth Hospital
Oct – Dec 2002	House officer, Department of medicine, Queen Mary Hospital
Jul – Sep 2002	House officer, Department of surgery, Kwong Wah Hospital

EXPERIENCE OF PARTICIPATION INTO CLINICAL TRIALS

Principal investigator of 30 clinical trials on lung cancers, nasopharyngeal cancer, gastrointestinal cancers and co-investigator in 45 clinical trials on primary CNS tumours, breast cancers, lung cancers and pancreatic cancers.

ORGANIZER AND CONVENOR OF INTERNATIONAL CONFERENCES/SYMPPOSIA

1. Organising committee – Hong Kong International Oncology Forum cum 4th Hong Kong-Shenzhen International Cancer Congress 6-9 September 2018
2. Organising committee – Sanming project of Medicine – The First International Symposium on Specialist Education and Advances in Radiation Oncology 2-3 December 2017
3. Organising committee – Hong Kong International Oncology Forum cum 3rd Hong Kong-Shenzhen International Cancer Congress 12-14 May 2017
4. Organiser – Hong Kong-Shenzhen International Cancer Congress on 21 November 2015
5. Organiser – Hong Kong Nasopharyngeal Carcinoma Symposium on 23-24 August 2014
6. Organiser – Hong Kong-Shenzhen International Cancer Congress on 22 November 2014
7. Organising committee – Hong Kong International Cancer Congress on 21 November 2014
8. Organising committee – Hong Kong International Cancer Congress on 14-15 November 2013

Research and Scholarship

- (1) *Scholarly books, monographs and chapters (Total 2)*

Monograph

1. **Lee VHF.** Treatment optimization of nasopharyngeal carcinoma (NPC) in the era of intensity modulated radiation therapy (IMRT). Doctor of Medicine (MD) Thesis 2015, The University of Hong Kong

Book Chapter

1. **Lee VHF (first author),** Chang ATY, Ng WT, Lee AWM. A book chapter on “Chemoradiotherapy: Concurrent Uses, Efficacy and Impact on Prognosis” published in 2016 by Nova Science Publishers, Inc.

Four Most Significant Publications in the Past Six Years

1. **Lee VH (first author),** Tin VP, Choy TS, Lam KO, Choi CW, Chung LP, Tsang JW, Ho PP, Leung DK, Ma ES, Liu J, Shek TW, Kwong DL, Leung TW, Wong MP. Association of Exon 19 and 21 EGFR Mutation Patterns with Treatment Outcome after First-Line Tyrosine Kinase Inhibitor in Metastatic Non-Small-Cell Lung Cancer. *J Thorac Oncol* 2013;8:1148-1155. (**Rank 33/213 in the category of Oncology**) (**Impact factor 5.040; 5-year impact factor 4.932; number of citations: 12**) (**Percentage of contribution: 30%**) (**Principal investigator**) (**This is the first study in the world showing differential response of different subtypes of exon 19 mutations to 1st EGFR-TKI therapy in metastatic non-small cell lung cancer**)
2. **Lee VHF (first and corresponding author),** Ng SCY, Leung TW, Au GKH, Kwong DLW. Dosimetric predictors for radiation-induced acute nausea and vomiting in IMRT for nasopharyngeal carcinoma. *Int J Radiat Oncol Biol Phys* 2012;84(1):176-182. (**Rank 46/213 in the category of Oncology**) (**Rank 2/25 in the category of Radiation Oncology**) (**Impact factor 4.495; 5-year impact factor 4.379; number of citations: 3**) (**International journal, externally referred**) (**Percentage of contribution: 100%**) (**Principal investigator**) (**This is the first study in the world showing vestibules are the organs responsible for radiation-induced acute nausea in IMRT for nasopharyngeal carcinoma. The journal ranks 1st in the field of radiation oncology**)
3. **Lee VHF (first and corresponding author),** Kwong DLW, Leung TW, Choi CW, Lai V, Ng L, Lam KO, Ng SCY, Sze CK, Tong CC, Ho PPY, Chan WL, Wong LS, Leung DKC, Chan SY, Khong PL. Early Undetectable Plasma EBV DNA to Predict long-term outcomes of non-metastatic nasopharyngeal carcinoma treated with radical intensity-modulated radiation therapy. *Oncotarget* 2017;8(3):5292-5308. (**Impact factor: 5.138; 5-year impact factor: 5.415; number of citations: 0**) (**International journal, externally reviewed**) (**Percentage of contribution: 100%**) (**Principal investigator**)
4. Smith C, **Lee V (co-first author),** Schuessler A, Beagley L, Rehan S, Tsang J, Smith D, Neller M, Matthews KK, Gostick E, Price DA, Burrows J, Boyle GM, Chua D, Panizza B, Porceddu SV, Nicholls J, Kwong D, Khanna R. Pre-emptive and Therapeutic Adoptive Immunotherapy for Nasopharyngeal Carcinoma: Phenotypic and Effector Function of T cells Impact on Clinical Response.

Oncoimmunology 2017;6(2):e1273311. (**Impact factor: 7.719, 5-year impact factor: 6.921; number of citations 0**) (International journal, externally reviewed) (Percentage of contribution: 100%) (Co-investigator)

(2) Journal publications (Total 91)

First or Corresponding Author (Total 27)

1. Lee VHF (first and corresponding author). Shifting the paradigm for maintenance therapy for non-small cell lung cancer. Hong Kong J Radiol 2010;13(Suppl):S16-21. (**Impact factor: 0; 5-year impact factor: 0; number of citations: unknown**) (Local journal, externally referred) (Percentage of contribution: 100%) (Principal investigator)

2. Lee VHF (first and corresponding author), Ng SCY, Leung TW, Au GKH, Kwong DLW. Dosimetric predictors for radiation-induced acute nausea and vomiting in IMRT for nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2012;84(1):176-182. (**Rank 46/213 in the category of Oncology**) (**Rank 2/25 in the category of Radiation Oncology**) (**Impact factor 4.495; 5-year impact factor 4.379; number of citations: 3**) (International journal, externally referred) (Percentage of contribution: 100%) (Principal investigator)

3. Lee VH (first and corresponding author), Ng SC, Choi CW, Luk MY, Leung TW, Au GKH, Kwong DLW. Comparative analysis of dosimetric parameters of three different radiation techniques for patients with Graves' ophthalmopathy treated with retro-orbital irradiation. Radiat Oncol 2012 Nov 26;7(1):199 (**Rank 132/213 in the category of Oncology**) (**Rank 7/25 in the category of Radiation Oncology**) (Impact factor 2.446; 5-year impact factor 2.768; number of citations: 0) (International journal, externally referred) (Percentage of contribution: 100%) (Principal investigator)

This article is the top 1 of similar article in the Domain of Article 23181900 “dosimetric study in radiation oncology” since its publication in 2012, as reported by BioMedLib

4. Lee VH (first author), Tin VP, Choy TS, Lam KO, Choi CW, Chung LP, Tsang JW, Ho PP, Leung DK, Ma ES, Liu J, Shek TW, Kwong DL, Leung TW, Wong MP. Association of exon 19 and 21 EGFR mutation patterns with treatment outcome after first-line tyrosine kinase inhibitor in metastatic non-small-cell lung cancer. J Thorac Oncol 2013;8:1148-55. (**Rank 33/213 in the category of Oncology**) (**Impact factor 5.040; 5-year impact factor 4.932; number of citations: 12**) (Percentage of contribution: 30%) (Principal investigator)

5. Lee VHF (first and corresponding author), Kwong DLW. Palliative Chemotherapy and Targeted Therapy for Recurrent and Metastatic Nasopharyngeal Carcinoma: Reminiscences and the Future. Hong Kong J Radiol 2013;16:252-260. DOI: 10.12809/hkjr1313185. (**Impact factor: not available; number of citations: 0**) (Local journal, externally referred) (Percentage of contribution: 30%) (Principal investigator) This article is published by invitation of Hong Kong College of Radiologists

6. Fang W, Lam K, Ng S, Choi C, Kwong D, Zeng S, **Lee V (corresponding author)**. Manual contouring based volumetric evaluation for colorectal cancer with liver limited metastases: a comparison with RECIST. *Asian Pac J Cancer Prev* 2013;14(7):4151-5. (**Impact factor 1.500; 5-year impact factor 1.538; number of citations: 0**) (**Regional journal, externally referred**) (**Percentage of contribution: 30%**) (**Project leader and co-principal investigator**)
7. Chung JCK, **Lee VHF (co-first and corresponding author)**, Tsang RKY, Chan JYW, Kwong DLW, Lam KO, Sze HCK, Leung TW. Treatment outcomes of post-radiation second head and neck malignancies (PRT-SHNM) managed by a multidisciplinary approach. *Head Neck* 2015;37(6):815-22. (**Rank 3/43 in the category of Otorhinolaryngology**) (**Impact factor 2.760; 5-year impact factor 2.790; number of citations: 1**) (**International journal, externally referred**) (**Percentage of contribution: 100%**) (**Project leader and principal investigator**)
8. **Lee VHF (first and corresponding author)**, Fang WJ, Lam KO, Choi CW, Ng SCY, Ho GCL, Cheng TKC, Ho PPY, Liu RKY, Leung TW, Kwong DLW, Zheng SS. Impact of CAPOX or FOLFOX on spleen size, platelet count and liver function when partnered cetuximab as first-line treatment for KRAS wild-type metastatic colorectal cancer. *Cancer Research Frontiers* 2015;1(1):60-74. (**Impact factor: not available; 5-year impact factor: not available; number of citations: 0**) (**International journal, externally referred**) (**Percentage of contribution: 100%**) (**Project leader and principal investigator**)
9. **Lee VHF (first and corresponding author)**, Chan WWL, Lee EYP, Choy TS, Ho PPY, Leung DKC, Lam KO, Kwong DLW, Leung TW, Khong PL. Prognostic significance of standardized uptake value of lymph nodes on survival for stage III non-small-cell lung cancer treated with definitive concurrent chemoradiotherapy. *Am J Clin Oncol* 2016;39(4):355-62. (**Rank 101/213 in the category of Oncology**) (**Rank 6/25 in the category of Radiation Oncology**) (**Impact factor 2.977; 5-year impact factor 2.447; number of citations: 1**) (**International journal, externally referred**) (**Percentage of contribution: 100%**) (**Principal investigator**)
10. Seneviratne CJ, Fong PHL, Wong SSW, **Lee VHF. (Project leader of research granted by RFCID fund and corresponding author)**. Antifungal susceptibility and phenotypic characterization of oral isolates of a black fungus from a nasopharyngeal carcinoma patient under radiotherapy. *BMC Oral Health* 2015;Mar 20;15:39. (**Rank 50/89 in the category of Dentistry, Oral Surgery & Medicine**) (**Impact factor 1.210; 5-year impact factor: 1.423; number of citations: 0**) (**International journal, externally referred**) (**Percentage of contribution: 30%**) (**Principal investigator**)
11. **Lee VHF (first and corresponding author)**, Leung DKC, Luk MY, Tong CC, Law MWM, Ng SCY, Tso WK, Wong KK, Liu RKY, Roon RTP, Kwong DLW, Leung TW. Yttrium-90 Radioembolization for Advanced Inoperable Hepatocellular Carcinoma. *OncoTargets and Therapy*

2015;8:3457-64. (**Rank 137/213 in the category of Oncology**) (**Impact factor: 2.272; 5-year impact factor: 2.235; number of citations: 0**) (**International journal, externally referred**) (**Percentage of contribution: 100%**) (**Principal investigator**)

12. **Lee VHF (first and corresponding author)**, Kwong DLW, Leung TW, Choi CW, Lam KO, Sze HCK, Ho PPY, Chan WL, Wong LS, Leung DKC, Chan SY, Chan FT. Post-radiation plasma EBV DNA and local clinical remission after radical intensity-modulated radiation therapy for nasopharyngeal carcinoma. *Clin Oncol* 2016; 28(1):42-9. (**Rank 87/213 in the category of Oncology**) (**Rank 5/25 in the category of Radiation Oncology**) (**Impact factor: 3.212; 5-year impact factor: 3.229; number of citations: 0**) (**International journal, externally referred**) (**Percentage of contribution: 100%**) (**Principal investigator**)

13. **Lee VHF (first and corresponding author)**, Leung DKC, Choy TS, Lam KO, Choi HY, Lam PM, Hui CYT, Leung TW, Kwong DLW. Efficacy and safety of afatinib in Chinese patients with EGFR-mutated metastatic non-small cell lung cancer previously responsive to 1st generation tyrosine-kinase inhibitors and chemotherapy: comparison with historical cohort using erlotinib in the same setting. *BMC Cancer* 2016; Feb 24;16:147 (**Rank 85/213 in the Category of Oncology**) (**Impact factor: 3.265; 5-year impact factor: 3.642; number of citations: 0**) (**International journal, externally referred**) (**Percentage of contribution: 100%**) (**Principal investigator**)

14. Wang DD, **Lee VHF (corresponding author)**, Ma LC, Zou B, Yan H. Selectivity Profile of Afatinib for EGFR-mutated non-small-cell lung cancer. *Molecular BioSystems* 2016;12(5):1552-63. (**Rank 134/289 in the Category of Biochemistry & Molecular Biology**) (**Impact factor: 2.829; 5-year impact factor: 2.807; number of citations: 0**) (**International journal, externally referred**) (**Percentage of contribution: 60%**) (**Principal investigator**)

15. **Lee VHF (first and corresponding author)**, Lam KO, Leung TW, Kwong DLW. Radiation recall after capecitabine for a patient with recurrent nasopharyngeal carcinoma. *J Med Case Rep* 2016;10(1):247. (**Impact factor: 0; 5-year impact factor: 0; number of citations: 0**) (**International journal, externally referred**) (**Percentage of contribution: 100%**) (**Principal investigator**)

16. **Lee VHF (first and corresponding author)**, Chan SY, Choi CW, Kwong DLW, Lam KO, Tong CC, Sze CK, Ng SCY, Leung TW. Dosimetric predictors of hypothyroidism after radical intensity-modulated radiation therapy for nasopharyngeal carcinoma. *Clin Oncol (R Coll Radiol)* 2016;28(8):e52-60. (**Rank 87/213 in the category of Oncology**) (**Rank 5/25 in the category of Radiation Oncology**) (**Impact factor: 3.212; 5-year impact factor: 3.229; number of citations: 0**) (**International journal, externally reviewed**) (**Percentage of contribution: 100%**) (**Principal investigator**)

17. **Lee VH (first and corresponding author)**, Lo AW, Leung CY, Shek WH, Kwong DL, Lam KO,

Tong CC, Sze CK, Leung TW. Correlation of PD-L1 expression of tumor cells with survival outcomes after radical intensity-modulated radiation therapy for non-metastatic nasopharyngeal carcinoma. PLoS One 2016;11(6):e0157969. (**Rank 11/63 in the category of Multidisciplinary Sciences**) (**Impact factor: 3.057; 5-year impact factor: 3.535; number of citations: 0**) (**International journal, externally reviewed**) (**Percentage of contribution: 100%**) (**Principal investigator**)

18. **Lee VHF (first and corresponding author)**. The aftermath of LUX-Lung 7 study—what have we learnt from it? Ann Transl Med 2016;4(15):294. (**Impact factor: 0; 5-year impact factor: 0; number of citations: 0**) (**International journal, externally reviewed**) (**Percentage of contribution: 100%**) (**Principal investigator**)

19. **Lee VHF (first and corresponding author)**, Kwong DLW, Leung TW, Ng SCY, Lam KO, Tong CC, Sze CK. Hyperfractionation compared to standard fractionation in intensity-modulated radiation therapy for patients with locally advanced recurrent nasopharyngeal carcinoma. Eur Arch Otorhinolaryngol 2017;274(2):1067-1078. (**Rank 18/43 in the category of Otorhinolaryngology**) (**Impact factor 1.627; 5-year impact factor: 1.630; number of citations 0**) (**International journal, externally referred**) (**Percentage of contribution: 100%**) (**Principal investigator**)

20. **Lee VHF (first and corresponding author)**, Kwong DLW, Leung TW, Choi CW, Lai V, Ng L, Lam KO, Ng SCY, Sze CK, Tong CC, Ho PPY, Chan WL, Wong LS, Leung DKC, Chan SY, Khong PL. Early Undetectable Plasma EBV DNA to Predict long-term outcomes of non-metastatic nasopharyngeal carcinoma treated with radical intensity-modulated radiation therapy. Oncotarget 2017;8(3):5292-5308. (**Impact factor: 5.008; 5-year impact factor: 5.415; number of citations: 0**) (**International journal, externally reviewed**) (**Percentage of contribution: 100%**) (**Principal investigator**)

21. **Lee VHF (first and corresponding author)**, Kwong DLW, Lam KO, Lai YC, Li Y, Tong CC, Ho PPY, Chan WL, Wong LS, Leung DKC, Chan SY, Chan FT, Leung TW, Lee AWM. Metronomic oral cyclophosphamide as third-line systemic treatment or beyond in patients with inoperable locoregionally advanced recurrent or metastatic nasopharyngeal carcinoma. Medicine 2016 (accepted for publication) (**Impact factor: 2.113, 5-year impact factor: 2.296; number of citations 0**) (**International journal, externally reviewed**) (**Percentage of contribution: 100%**) (**Principal investigator**)

22. **Lee VHF (first and corresponding author)**. How far have we achieved by systemic therapy for recurrent/metastatic nasopharyngeal carcinoma? Transl Cancer Res 2017 (accepted for publication) (**Impact factor: 1.757, 5-year impact factor: 1.633; number of citations 0**) (**International journal, externally reviewed**) (**Percentage of contribution: 100%**) (**Principal investigator**)

23. Smith C, **Lee V (co-first author)**, Schuessler A, Beagley L, Rehan S, Tsang J, Smith D, Neller M, Matthews KK, Gostick E, Price DA, Burrows J, Boyle GM, Chua D, Panizza B, Porceddu SV, Nicholls

J, Kwong D, Khanna R. Pre-emptive and Therapeutic Adoptive Immunotherapy for Nasopharyngeal Carcinoma: Phenotypic and Effector Function of T cells Impact on Clinical Response. Oncoimmunology 2017;6(2):e1273311. (**Impact factor: 7.719, 5-year impact factor: 6.921; number of citations 0**) (**International journal, externally reviewed**) (**Percentage of contribution: 100%**) (**Co-investigator**)

24. **Lee V (first and corresponding author)**, Kwong D, Leung TW, Lam KO, Tong CC, Lee A. Palliative systemic therapy for recurrent or metastatic nasopharyngeal carcinoma - How far have we achieved? Crit Rev Oncol Hematol 2017;114:13-23.

25. **Lee VHF (first and corresponding author)**, Ng SCY, Kwong DLW, Lam KO, Leung TW. Impact of intravenous contrast used in computed tomography on radiation dose to carotid arteries and thyroid in intensity-modulated radiation therapy planning for nasopharyngeal carcinoma. Med Dosim 2017;42(2):137-144.

26. Zou B, **Lee VHF (corresponding author)**, Chen LJ, Ma LC, Wang DD, Yan H. Deciphering mechanisms of acquired T790M mutation after EGFR inhibitors for NSCLC by computational simulations. Sci Reports 2017;7(1):6595v. (**Impact factor: 4.259, 5-year impact factor: 4.847; number of citations 0**) (**International journal, externally reviewed**) (**Percentage of contribution: 50%**) (**Co-investigator**)

27. **Lee VHF (first and corresponding author)**, Chan SY, Tong CC, Lam KO, Kwong DLW, Lee AWM, Leung TW. New hope for advanced nasopharyngeal cancer – an Epstein-Barr virus-driven endemic malignancy? Trans Cancer Res 2018 (in press).

Co-authors (Total 64)

1. Chua DTT, Hung KN, **Lee VHF**, Ng CY, Tsang JWH. Validation of a prognostic scoring system for locally recurrent nasopharyngeal carcinoma treated by stereotactic radiosurgery. BMC Cancer, 2009;9:131. (**Rank 85/213 in the Category of Oncology**) (**Impact factor 3.265; 5-year impact factor 3.642; number of citations: 2**) (**International journal, externally referred**) (**Percentage of contribution: 30%**) (**Co-investigator**)

2. Chua DTT, Wu SX, **Lee VHF**, Tsang JWH. Comparison of single versus fractionated dose of stereotactic radiotherapy for salvaging local failures of nasopharyngeal carcinoma: a matched-cohort analysis, Head & Neck Oncology 2009;1:13. (**Impact factor: not available as it is ceased to publish; number of citations: 6**) (**International journal, externally referred**) (**Percentage of contribution: 30%**) (**Co-investigator**)

3. Wong FCS, Ng AWY, **Lee VHF**, Yuen KK, Lui CMM, Sze WK, Leung TW, Tung SY. Whole-field simultaneous integrated-boost intensity-modulated radiotherapy for patients with nasopharyngeal

carcinoma, Int J Radiat Oncol Biol Phys 2010;76(1):138-145. (**Rank 46/213 in the category of Oncology**) (**Rank 2/25 in the category of Radiation Oncology**) (**Impact factor 4.495; 5-year impact factor 4.379; number of citations: 23**) (**International journal, externally referred**) (**Percentage of contribution: 30%**) (**Co-investigator**)

4. Ho ACW, **Lee VHF**, To VSH, Kwong DLW, Wei WI. Natural course and tumor doubling time of nasopharyngeal carcinoma. A study of 15 patients. Oral Oncol 2011;47(8):742-746. (**Impact factor 4.286; 5-year impact factor 3.752; number of citations: 1**) (**International journal, externally referred**) (**Percentage of contribution: 40%**) (**Co-investigator**)

5.Tse VC, Ng WT, **Lee VHF**, Lee AWM, Chua DTT, Chau J, McGhee SH. Cost-analysis of XELOX and FOLFOX4 for treatment of colorectal cancer to assist decision-making on reimbursement. BMC Cancer 2011 Jul 9;11:288. (**Rank 85/213 in the Category of Oncology**) (**Impact factor 3.265; 5-year impact factor 3.642; number of citations: 4**) (**International journal, externally referred**) (**Percentage of contribution: 30%**) (**Co-investigator**)

6. Chan YW, **Lee VH**, Chow VL, To VS, Wei WI. Extracapsular lymph node spread in recurrence nasopharyngeal carcinoma. Laryngoscope 2011;121(12):2576-2580. (**Rank 9/43 in the Category of Otorhinolaryngology**) (**Rank 67/124 in the Category of Medicine, Research & Experimental**) (**Impact factor 2.272; 5-year impact factor 2.452; number of citations: 0**) (**International journal, externally referred**) (**Percentage of contribution: 30%**) (**Co-investigator**)

7. Lan Q, Hsiung CA, Matsuo K, Hong YC, Seow A, Wang Z, Hosgood HD 3rd, Chen K, Wang JC, Chatterjee N, Hu W, Wong MP, Zheng W, Caporaso N, Park JY, Chen CJ, Kim YH, Kim YT, Landi MT, Shen H, Lawrence C, Burdett L, Yeager M, Yuenger J, Jacobs KB, Chang IS, Mitsudomi T, Kim HN, Chang GC, Bassig BA, Tucker M, Wei F, Yin Z, Wu C, An SJ, Qian B, **Lee VH**, Lu D, Liu J, Jeon HS, Hsiao CF, Sung JS, Kim JH, Gao YT, Tsai YH, Jung YJ, Guo H, Hu Z, Hutchinson A, Wang WC, Klein R, Chung CC, Oh IJ, Chen KY, Berndt SI, He X, Wu W, Chang J, Zhang XC, Huang MS, Zheng H, Wang J, Zhao X, Li Y, Choi JE, Su WC, Park KH, Sung SW, Shu XO, Chen YM, Liu L, Kang CH, Hu L, Chen CH, Pao W, Kim YC, Yang TY, Xu J, Guan P, Tan W, Su J, Wang CL, Li H, Sihoe AD, Zhao Z, Chen Y, Choi YY, Hung JY, Kim JS, Yoon HI, Cai Q, Lin CC, Park IK, Xu P, Dong J, Kim C, He Q, Perng RP, Kohno T, Kweon SS, Chen CY, Vermeulen R, Wu J, Lim WY, Chen KC, Chow WH, Ji BT, Chan JK, Chu M, Li YJ, Yokota J, Li J, Chen H, Xiang YB, Yu CJ, Kunitoh H, Wu G, Jin L, Lo YL, Shiraishi K, Chen YH, Lin HC, Wu T, Wu YL, Yang PC, Zhou B, Shin MH, Fraumeni JF Jr, Lin D, Chanock SJ, Rothman N. Genome-wide association analysis identifies new lung cancer susceptibility loci in never-smoking women in Asia. Nat Genet 2012;44(12):1330-1335. (**Rank 2/165 in the category of Genetics & Heredity**) (**Impact factor 31.616; 5-year impact factor 32.197; number of citations: 54**) (**International journal, externally referred**) (**Percentage of contribution: 5%**) (**Co-investigator**) (**This is an Asian GWAS study on lung cancer initiated by National Institute of Health, USA**)

8. Smith C, Tsang J, Beagley L, Chua D, **Lee V**, Li V, Moss DJ, Coman W, Chan KH, Nicholls J, Kwong D, Khanna R. Effective treatment of metastatic forms of Epstein-barr virus-associated nasopharyngeal carcinoma with a novel adenovirus-based adoptive immunotherapy. *Cancer Res* 2012;72(5):1116-1125. (**Rank 13/213 in the category of Oncology**) (**Impact factor 8.556; 5-year impact factor 9.241; number of citations: 24**) (**International journal, externally referred**) (**Percentage of contribution: 20%**) (**Co-investigator**)
9. Wong CS, Gong N, Chu YC, Anthony MP, Chan Q, **Lee HF**, Chu KM, Khong PL. Correlation of measurements from diffusion weighted MR imaging and FDG PET/CT in GIST patients: ADC versus SUV. *Eur J Radiol* 2012;81(9):2122-2126. (**Rank 36/124 in the category of Radiology, Nuclear Medicine & Medical Imaging**) (**Impact factor 2.593; 5-year impact factor 2.518; number of citations: 7**) (**International journal, externally referred**) (**Percentage of contribution: 20%**) (**Co-investigator**)
10. Pow EH, Kwong DL, Sham JS, **Lee VH**, Ng SC. Can intensity-modulated radiotherapy preserve oral health-related quality of life of nasopharyngeal carcinoma patients? *Int J Radiat Oncol Biol Phys* 2012;83(2):e213-221. (**Rank 46/213 in the category of Oncology**) (**Rank 2/25 in the category of Radiation Oncology**) (**Impact factor 4.495; 5-year impact factor 4.379; number of citations: 0**) (**International journal, externally referred**) (**Percentage of contribution: 20%**) (**Co-investigator**)
11. Zhang LY, **Lee VHF**, Wong AM, Kwong DL, Zhu YH, Dong SS, Kong KL, Chen J, Tsao SW, Guan XY, Fu L. MicroRNA-144 promotes cell proliferation, migration and invasion in nasopharyngeal carcinoma through repression of PTEN. *Carcinogenesis* 2013 Feb;34(2):454-63. (**Rank 37/213 in the category of Oncology**) (**Impact factor 4.874; 5-year impact factor 5.368, number of citations: 35**) (**International journal, externally referred**) (**Percentage of contribution: 35%**) (**Principal supervisor of first author for her PhD**)
12. Lam KO, **Lee VH**. Metastatic colorectal cancer: optimizing treatment with anti-EGFR monoclonal antibody. *J Cancer Therapy* 2012;3:902-911. (**Impact factor: not available, number of citations: 0**) (**International journal, externally referred**) (**Percentage of contribution: 40%**) (**Co-investigator**)
13. Lam KO, **Lee VH**, Liu RK, Leung TW, Kwong DL. Bevacizumab-containing regimens after cetuximab failure in Kras wild-type metastatic colorectal carcinoma. *Oncol Lett*. 2013 Feb;5(2):637-640. (**Rank 181/213 in the category of Oncology**) (**Impact factor: 1.482; 5-year impact factor: 1.448; number of citations: 1**) (**International journal, externally referred**) (**Percentage of contribution: 30%**) (**Co-investigator**)
14. Lai V, Li X, **Lee VH**, Lam KO, Chan Q, Khong PL. Intravoxel incoherent motion MR imaging: comparison of diffusion and perfusion characteristics between nasopharyngeal carcinoma and post-chemoradiation fibrosis. *Eur Radiol* 2013;23(10):2793-2801. (**Rank 18/124 in the category of Radiology, Nuclear Medicine & Medical Imaging**) (**Impact factor 2.593; 5-year impact factor 2.518; number of citations: 10**) (**International journal, externally referred**) (**Percentage of contribution: 30%**) (**Co-investigator**)

Radiology, Nuclear Medicine & Medical Imaging) (Impact factor 3.640; 5-year impact factor 3.934; number of citations: 4) (International journal, externally referred) (Percentage of contribution: 40%) (Co-investigator)

15. Wu YL, Lee JS, Thongprasert S, Yu CJ, Zhang L, Ladrera G, Srimuninnimit V, Sriuranpong V, Sandoval-Tan J, Zhu Y, Liao M, Zhou C, Pan H, **Lee V**, Chen YM, Sun Y, Margono B, Fuerte F, Chang GC, Seetalarom K, Wang J, Cheng A, Syahruddin E, Qian X, Ho J, Krunianda J, Liu HE, Jin K, Truman M, Bara I, Mok T. Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-lung cancer (FASTACT-2): a randomised, double-blind trial. Lancet Oncol 2013;14:777-786. **(Rank 3/213 in the category of Oncology) (Impact factor 26.509; 5-year impact factor 28.181; number of citations: 41) (International journal, externally referred) (Percentage of contribution: 30%) (Site principal investigator)**

16. Lai V, Li X, **Lee VH**, Lam KO, Fong DY, Huang B, Chan Q, Khong PL. Nasopharyngeal carcinoma: comparison of diffusion and perfusion characteristics between different tumour stages using intravoxel incoherent motion MR imaging. Eur Radiol 2014;24:176-183. **(Rank 18/124 in the category of Radiology, Nuclear Medicine & Medical Imaging) (Impact factor 3.640; 5-year impact factor 3.934; number of citations: 0) (International journal, externally referred) (Percentage of contribution: 40%) (Co-investigator)**

17. Ng SC, **Lee VH**, Law MW, Liu RK, Ma VW, Tso WK, Leung TW. Patient dosimetry for 90Y selective internal radiation treatment based on 90Y PET imaging. J Appl Clin Med Phys 2013 Sep 6;14(5):4371. **(Rank 88/124 in the category of Radiology, Nuclear Medicine & Medical Imaging) (Impact factor 1.444; 5-year impact factor 1.434; number of citations: 4) (International journal, externally referred) (Percentage of contribution: 30%) (Co-investigator)**

18. Wang DD, Zhou W, Yan H, Wong M, **Lee V**. Personalized prediction of EGFR mutation-induced drug resistance in lung cancer. Sci Rep. 2013 Oct 4;3:2855. **(Rank 7/63 in the category of Multidisciplinary Sciences) (Impact factor 5.228; 5-year impact factor 5.525; number of citations: 4) (International journal, externally referred) (Percentage of contribution: 25%) (Co-investigator)**

19. Lee VW, Schwander B, **Lee VH**. Effectiveness and cost-effectiveness of erlotinib versus gefitinib in first-line treatment of epidermal growth factor receptor-activating mutation-positive non-small-cell lung cancer patients in Hong Kong. Hong Kong Med J 2014;20(3):178-186. **(Rank 96/151 in the category of Medicine, General & Internal) (Impact factor: 0.887; number of citations: 1) (Local journal, externally referred) (Percentage of contribution: 30%) (Co-investigator)**

20. Tsang JWH, **Lee VHF**, Kwong DLW. Novel therapy for nasopharyngeal carcinoma – Where are we. Oral Oncol 2014;50(9):798-801. **(Rank 3/89 in the category of Dentistry Oral Surgery & Medicine)**

(Rank 52/213 in the category of Oncology) (Impact factor: 4.286; 5-year impact factor; 3.752; number of citations: 1) (International journal, externally referred) (Percentage of contribution: 30%) (Co-investigator)

21. Chan WL, Lee VHF, Siu SWK, Leung TW. Inoperable Adenoid Cystic Carcinoma of Trachea: Complete Remission after Multi-modality Treatment. Hong Kong J Radiol 2014;17:203-7. **(Impact factor: not available; number of citations: 0) (Local journal, externally referred) (Percentage of contribution: 30%) (Co-investigator)**
22. Chan WL, Lee VH, Siu WK, Ho PY, Liu RK, Leung TW. Biweekly cetuximab and first-line chemotherapy in chinese patients with k-ras wild-type colorectal cancers. South Asian J Cancer. 2014 Jul;3(3):175-8. doi: 10.4103/2278-330X.136802. **(Impact factor: not available; number of citations: 0) (Regional journal, externally referred) (Percentage of contribution: 40%) (Co-investigator)**
23. Mok TS, Geater SL, Iannotti N, Thongprasert S, Spira A, Smith D, Lee V, Lim WT, Reyderman L, Wang B, Gopalakrishna P, Garzon F, Xu L, Reynolds C. Randomised phase II study of two intercalated combinations of eribulin mesilate and erlotinib in patients previously pretreated advanced non-small cell lung cancer. Ann Oncol 2014;25(8):1578-84. **(Rank 11/213 in the category of Oncology) (Impact factor 9.269; 5-year impact factor 7.828, number of citations: 1) (International journal, externally referred) (Percentage of contribution: 30%) (Site principal investigator)**
24. Machiela MJ, Hsiung CA, Shu XO, Seow WJ, Wang Z, Matsuo K, Hong YC, Seow A, Wu C, Hosgood HD 3rd, Chen K, Wang JC, Wen W, Cawthon R, Chatterjee N, Hu W, Caporaso NE, Park JY, Chen CJ, Kim YH, Kim YT, Landi MT, Shen H, Lawrence C, Burdett L, Yeager M, Chang IS, Mitsudomi T, Kim HN, Chang GC, Bassig BA, Tucker M, Wei F, Yin Z, An SJ, Qian B, Lee VH, Lu D, Liu J, Jeon HS, Hsiao CF, Sung JS, Kim JH, Gao YT, Tsai YH, Jung YJ, Guo H, Hu Z, Hutchinson A, Wang WC, Klein RJ, Chung CC, Oh JJ, Chen KY, Berndt SI, Wu W, Chang J, Zhang XC, Huang MS, Zheng H, Wang J, Zhao X, Li Y, Choi JE, Su WC, Park KH, Sung SW, Chen YM, Liu L, Hyun Kang C, Hu L, Chen CH, Pao W, Kim YC, Yang TY, Xu J, Guan P, Tan W, Su J, Wang CL, Li H, Dart Loon Sihoe A, Zhao Z, Chen Y, Choi YY, Hung JY, Kim JS, Yoon HI, Cai Q, Lin CC, Park IK, Xu P, Dong J, Kim C, He Q, Perng RP, Kohno T, Kweon SS, Chen CY, Vermeulen RC, Wu J, Lim WY, Chen KC, Chow WH, Ji BT, Chan JK, Chu M, Li YJ, Yokota J, Li J, Chen H, Xiang YB, Yu CJ, Kunitoh H, Wu G, Jin L, Lo YL, Shiraishi K, Chen YH, Lin HC, Wu T, Pik Wong M, Wu YL, Yang PC, Zhou B, Shin MH, Fraumeni Jr JF, Zheng W, Lin D, Chanock SJ, Rothman N, Lan Q. Genetic variants associated with longer telomere length are associated with increased lung cancer risk among never-smoking women in Asia: A report from the female lung cancer consortium in Asia. Int J Cancer 2015;137:311-9. **(Rank 29/213 in the category of Oncology) (Impact factor 5.531; 5-year impact factor 5.624, number of citations: 8) (International journal, externally referred) (Percentage of contribution: 5%) (Co-investigator)**

25. Lai V, **Lee VH**, Lam KO, Sze HC, Chan Q, Khong PL. Intravoxel water diffusion heterogeneity MR imaging of nasopharyngeal carcinoma using stretched exponential diffusion model. Eur Radiol 2015;25(6):1708-13. (**Rank 18/124 in the category of Radiology, Nuclear Medicine & Medical Imaging**) (**Impact factor 3.640; 5-year impact factor 3.934, number of citations: 0**) (**International journal, externally referred**) (**Percentage of contribution: 40%**) (**Co-investigator**)
26. Wong KW, Kwong DLW, Khong PL, **Lee VHF**, Ng SCY, Law MWM. Delineation of biological tumor volume from positron emission tomography images in nasopharyngeal carcinoma. J Biomedical Science and Engineering 2014;7:857-865. (**Impact factor: 1.180; 5-year impact factor: not available; number of citations: 0**) (**International journal, externally referred**) (**Percentage of contribution: 25%**) (**Co-investigator**)
27. Lee EYP, Khong PL, **Lee VHF**, Qian WS, Wong MP. Metabolic phenotype of stage IV lung adenocarcinoma: relationship with epidermal growth factor receptor mutation. Clin Nucl Med 2015;40(3):e190-195. (**Rank 14/124 in the category of Radiology, Nuclear Medicine & Medical Imaging**) (**Impact factor 4.278; 5-year impact factor 3.430, number of citations: 0**) (**International journal, externally referred**) (**Percentage of contribution: 30%**) (**Co-investigator**)
28. Ma LC, Wang DD, Huang YQ, Yan H, Wong MP, **Lee VHF**. EGFR Mutant Structural Database: Computationally predicted 3D structures and the corresponding binding free energies with gefitinib and erlotinib. BMC Bioinformatics 2015;16:85 DOI: 10.1186/s12859-015-0522-3 (**Rank 39/77 in the category of Biochemical Research Methods**) (**Rank 64/161 in the category of Biotechnology & Applied Microbiology**) (**Rank 10/56 in the category of Mathematical & Computational Biology**) (**Impact factor: 2.435; 5-year impact factor: 3.443; number of citations: 0**) (**International journal, externally referred**) (**Percentage of contribution: 30%**) (**Co-investigator**)
29. Hui EP, Ma BBY, Chan KCA, Chan CML, Wong CSC, To KF, Chan AWH, Tung SY, Ng WT, Cheng AC, **Lee VHF**, Chan SL, Loong HHF, Kam MKM, Leung SF, Ho R, Mo F, Lo DYM, Ngan RKC, Chan ATC. Clinical utility of plasma EBV DNA and *ERCC1* single nucleotide polymorphism in nasopharyngeal carcinoma. Cancer 2015;121(16):2720-9. (**Rank 26/213 in the category of Oncology**) (**Impact factor 5.649; 5-year impact factor 5.434, number of citations: 2**) (**International journal, externally referred**) (**Percentage of contribution: 20%**) (**Co-investigator**)
30. Dai W, Cheung AKL, Ko JMY, Cheng Y, Zheng H, Ngan RKC, Ng WT, Lee AWM, Yau CC, **Lee VHF**, Li Lung M. Comparative Methylome Analysis in Solid Tumours Reveals Aberrant Methylation at Chromosome 6p in Nasopharyngeal Carcinoma. Cancer Med 2015;4(7):1079-90. (**Rank 107/213 in the category of Oncology**) (**Impact factor: 2.915; 5-year impact factor: 2.959; number of citations: 2**) (**International journal, externally referred**) (**Percentage of contribution: 10%**) (**Co-investigator**)

31. Wang DD, Ma LC, Wong MP, **Lee VHF**, Yan H. Contribution of EGFR and ErbB-3 heterodimerization to the EGFR Mutation-induced Gefitinib- and Erlotinib-resistance in Non-Small-Cell Lung Carcinoma Treatments. PLoS One 2015;10(5):e0128360 (**Rank 11/63 in the category of Multidisciplinary Sciences**) (**Impact factor: 3.057; 5-year impact factor: 3.535; number of citations: 0**) (**International journal, externally referred**) (**Percentage of contribution: 30%**) (**Co-investigator**)
32. Willowson KP, Tapner M, Ahmadzadehfar H, Amthauer H, Arbizu J, Attarwala AA, Bagni O, Benard F, Bonutti F, Botta F, Boucek JA, Bourgeois AC, Bradley YC, Buchholz H, Büsing K, Carlier T, Celler A, Cervo M, Civollani S, Conti M, Craig AJ, Cremonesi M, D'Andrea M, D'Arienzo M, D'Asseler Y, Di Martino F, Doss M, Duan H, Eugene T, Ferrari M, Filippi L, Flamen P, Fletcher AM, Flux GD, Fourkal E, Francis R, Freeman LM, Geatti O, Glatting G, Goedcke A, Großer OS, Habito CMR, Hallam A, Heard S, Hoffmann M, Holm S, Hooker CA, Iaccarino G, Jeans SP, Judy P, Julyan PJ, Kabasakal L, Kaiser H, Kappadath SC, Lambert B, Lassmann M, Law MW, **Lee VH**, Leek F, Lhommel R, Lodge MA, Lopez A, Luster M, Martí-Climent JM, McGowan DR, McKinney JM, McLamb B, Miederer M, Molina-Duran F, Moore SC, Morgen DG, Mortensen J, Mottaghay FM, Mulder RU, Munk OL, Muzaffar R, Ng SC, Nijran KS, de Nijs R, O'Keefe GJ, Osman MM, Ouyang J, Pasciak AS, Pettinato C, Pooley RA, Rausch IF, Reindl M, Rodriguez-Fraile M, Schlägl S, Schönberg SO, Sheikh A, Strigari L, Siman W, Song N, Srinivas SM, Staanum PF, Stone JR, Tanyildizi H, Towey DJ, Vanderlinde B, Weir G, Yu N, Bailey DL, A multicentre comparison of quantitative 90Y PET/CT for dosimetric purposes after radioembolization with resin microspheres. Eur J Nucl Med Mol Imaging 2015;42:1202-1222 (**Rank 6/124 in the category of Radiology, Nuclear Medicine & Medical Imaging**) (**Impact factor: 5.537; 5-year impact factor: 5.415; number of citations 2**) (**International journal, externally referred**) (**Percentage of contribution: 20%**) (**Site principal investigator**).
33. Sampson JN, Wheeler WA, Yeager M, Panagiotou O, Wang Z, Berndt SI, Lan Q, Abnet CC, Amundadottir LT, Figueroa JD, Landi MT, Mirabello L, Savage SA, Taylor PR, De Vivo I, McGlynn KA, Purdue MP, Rajaraman P, Adami HO, Ahlbom A, Albanes D, Amary MF, An SJ, Andersson U, Andriole G Jr, Andrulis IL, Angelucci E, Ansell SM, Arici C, Armstrong BK, Arslan AA, Austin MA, Baris D, Barkauskas DA, Bassig BA, Becker N, Benavente Y, Benhamou S, Berg C, Van Den Berg D, Bernstein L, Bertrand KA, Birmann BM, Black A, Boeing H, Boffetta P, Boutron-Ruault MC, Bracci PM, Brinton L, Brooks-Wilson AR, Bueno-de-Mesquita HB, Burdett L, Buring J, Butler MA, Cai Q, Cancel-Tassin G, Canzian F, Carrato A, Carreon T, Carta A, Chan JK, Chang ET, Chang GC, Chang IS, Chang J, Chang-Claude J, Chen CJ, Chen CY, Chen C, Chen CH, Chen C, Chen H, Chen K, Chen KY, Chen KC, Chen Y, Chen YH, Chen YS, Chen YM, Chien LH, Chirlaque MD, Choi JE, Choi YY, Chow WH, Chung CC, Clavel J, Clavel-Chapelon F, Cocco P, Colt JS, Comperat E, Conde L, Connors JM, Conti D, Cortessis VK, Cotterchio M, Cozen W, Crouch S, Crouse-Bou M, Cussenot O, Davis FG, Ding T, Diver WR, Dorronsoro M, Dossus L, Duell EJ, Ennas MG, Erickson RL, Feychtung M, Flanagan AM, Foretova L, Fraumeni JF Jr, Freedman ND, Beane Freeman LE, Fuchs C, Gago-Dominguez M, Gallinger S, Gao YT, Gapstur SM, Garcia-Closas M, García-Closas R, Gascoyne RD, Gastier-Foster J,

Gaudet MM, Gaziano JM, Giffen C, Giles GG, Giovannucci E, Glimelius B, Goggins M, Gokgoz N, Goldstein AM, Gorlick R, Gross M, Grubb R 3rd, Gu J, Guan P, Gunter M, Guo H, Habermann TM, Haiman CA, Halai D, Hallmans G, Hassan M, Hattinger C, He Q, He X, Helzlouer K, Henderson B, Henriksson R, Hjalgrim H, Hoffman-Bolton J, Hohensee C, Holford TR, Holly EA, Hong YC, Hoover RN, Horn-Ross PL, Hosain GM, Hosgood HD 3rd, Hsiao CF, Hu N, Hu W, Hu Z, Huang MS, Huerta JM, Hung JY, Hutchinson A, Inskip PD, Jackson RD, Jacobs EJ, Jenab M, Jeon HS, Ji BT, Jin G, Jin L, Johansen C, Johnson A, Jung YJ, Kaaks R, Kamineni A, Kane E, Kang CH, Karagas MR, Kelly RS, Khaw KT, Kim C, Kim HN, Kim JH, Kim JS, Kim YH, Kim YT, Kim YC, Kitahara CM, Klein AP, Klein RJ, Kogevinas M, Kohno T, Kolonel LN, Kooperberg C, Kricker A, Krogh V, Kunitoh H, Kurtz RC, Kweon SS, LaCroix A, Lawrence C, Lecanda F, Lee VH, Li D, Li H, Li J, Li YJ, Li Y, Liao LM, Liebow M, Lightfoot T, Lim WY, Lin CC, Lin D, Lindstrom S, Linet MS, Link BK, Liu C, Liu J, Liu L, Ljungberg B, Lloreta J, Di Lollo S, Lu D, Lund E, Malats N, Mannisto S, Le Marchand L, Marina N, Masala G, Mastrangelo G, Matsuo K, Maynadie M, McKay J, McKean-Cowdin R, Melbye M, Melin BS, Michaud DS, Mitsudomi T, Monnereau A, Montalvan R, Moore LE, Mortensen LM, Nieters A, North KE, Novak AJ, Oberg AL, Offit K, Oh IJ, Olson SH, Palli D, Pao W, Park IK, Park JY, Park KH, Patiño-Garcia A, Pavanello S, Peeters PH, Perng RP, Peters U, Petersen GM, Picci P, Pike MC, Porru S, Prescott J, Prokunina-Olsson L, Qian B, Qiao YL, Rais M, Riboli E, Riby J, Risch HA, Rizzato C, Rodabough R, Roman E, Roupret M, Ruder AM, Sanjose Sd, Scelo G, Schned A, Schumacher F, Schwartz K, Schwenn M, Scotlandi K, Seow A, Serra C, Serra M, Sesso HD, Setiawan VW, Severi G, Severson RK, Shanafelt TD, Shen H, Shen W, Shin MH, Shiraishi K, Shu XO, Siddiq A, Sierrasésúmaga L, Sihoe AD, Skibola CF, Smith A, Smith MT, Southey MC, Spinelli JJ, Staines A, Stampfer M, Stern MC, Stevens VL, Stolzenberg-Solomon RS, Su J, Su WC, Sund M, Sung JS, Sung SW, Tan W, Tang W, Tardón A, Thomas D, Thompson CA, Tinker LF, Tirabosco R, Tjønneland A, Travis RC, Trichopoulos D, Tsai FY, Tsai YH, Tucker M, Turner J, Vajdic CM, Vermeulen RC, Villano DJ, Vineis P, Virtamo J, Visvanathan K, Wactawski-Wende J, Wang C, Wang CL, Wang JC, Wang J, Wei F, Weiderpass E, Weiner GJ, Weinstein S, Wentzensen N, White E, Witzig TE, Wolpin BM, Wong MP, Wu C, Wu G, Wu J, Wu T, Wu W, Wu X, Wu YL, Wunder JS, Xiang YB, Xu J, Xu P, Yang PC, Yang TY, Ye Y, Yin Z, Yokota J, Yoon HI, Yu CJ, Yu H, Yu K, Yuan JM, Zelenetz A, Zeleniuch-Jacquotte A, Zhang XC, Zhang Y, Zhao X, Zhao Z, Zheng H, Zheng T, Zheng W, Zhou B, Zhu M, Zucca M, Boca SM, Cerhan JR, Ferri GM, Hartge P, Hsiung CA, Magnani C, Miligi L, Morton LM, Smedby KE, Teras LR, Vijai J, Wang SS, Brennan P, Caporaso NE, Hunter DJ, Kraft P, Rothman N, Silverman DT, Slager SL, Chanock SJ, Chatterjee N. Analysis of heritability and shared heritability based on genome-wide association studies for thirteen cancer types. *J Natl Cancer Inst* 2015; 107(12):djv279. **(Rank 9/213 in the category of Oncology) (Impact factor: 11.370; 5-year impact factor: 12.798; number of citations 0) (International journal, externally referred) (Percentage of contribution 10%) (Co-investigator)**

34. Yu VZ, Wong VCL, Mun-Yee Ko JMY, Lam AKY, Chan KW, Samant R, Hong Lok Lung HL, Dai W, Shuen WH, Law S, Chan YP, Lee NPY, Tong DKH, Law TT, Lee VHF, Li Lung M. Nuclear DNAJB6, a good independent prognostic marker for survival of late-onset metastasis-free esophageal

cancer patients, modulates Akt signaling and suppresses cancer cell proliferation. *Gastroenterology* 2015;149(7):1825-1836.e5. (**Rank 1/78 in the category of Gastroenterology & Hepatology**) (**Impact factor: 18.187; 5-year impact factor: 15.417; number of citations: 1**) (**International journal, externally referred**) (**Percentage of contribution: 10%**) (**Co-supervisor of first author for his PhD study and co-investigator**)

35. Zhang N, Fielding R, Soong I, Chan KK, Tsang J, **Lee V**, Lee C, Ng A, Sze WK, Tin P, Lam WW. Illness perceptions among cancer survivors. *Support Care Cancer* 2016;24(3):1295-304. (**Rank 127/213 in the category of Oncology**) (**Rank 24/87 in the category of Health Sciences & Services**) (**Rank 8/65 in the category of Rehabilitation**) (**Impact factor 2.535; 5-year impact factor: 2.689; number of citations: 0**) (**International journal, externally referred**) (**Percentage of contribution: 15%**) (**Co-investigator**)

36. Wang Z, Seow WJ, Shiraishi K, Hsiung CA, Matsuo K, Liu J, Chen KX, Yamji T, Yang Y, Chang IS, Wu C, Hong YC, Burdett L, Wyatt K, Chung CC, Li SCA, Yeager M, Hutchinson A, Hu W, Caporaso N, Land MT, Chatterjee N, Song MS, Fraumeni Jr JF, Kohno T, Yokota J, Kunitoh H, Ashikawa K, Momozawa Y, Daigo Y, Mitsudomi T, Yatabe Y, Hida T, Hu ZB, Dai JC, Ma HX, Jin GF, Song B, Wang ZH, Cheng SS, Yin ZH, Li XL, Ren YW, Guan P, Chang J, Tan W, Chen CJ, Chang GC, Tsai YH, Su WC, Chen KY, Huang MS, Chen YM, Zheng H, Li HX, Cui P, Guo H, Xu P, Liu L, Iwasaki M, Shimazu T, Tsugane S, Zhu JJ, Jiang GN, Fei K, Park JY, Kim YH, Sung JS, Park KH, Kim YT, Jung YJ, Kang CH, Park IK, Kim HN, Jeon HS, Choi JE, Choi YY, Kim JH, Oh IJ, Kim YC, Sung SW, Kim JS, Yoon HI, Kweon SS, Shin MH, Seow A, Chen Y, Lim WY, Liu JJ, Wong MP, **Lee VH**, Bassig BA, Tucker M, Berndt SI, Chow WH, Ji BT, Wang JW, Xu J, Sihoe ADL, Ho JCM, Chan JKC, Wang JC, Lu DR, Zhao XY, Zhao ZH, Wu JJ, Chen HY, Jin L, Wei FS, Wu GP, An SJ, Zhang XC, Su J, Wu YL, Gao YT, Xiang YB, He XZ, Li JH, Zheng W, Shu XO, Cai QY, Klein R, Pao W, Lawrence C, Hosgood III HD, Hsiao CF, Chien LH, Chen YH, Chen CH, Wang WC, Chen CY, Wang CL, Yu CJ, Chen HL, Su YC, Tsai FY, Chen YS, Li YJ, Yang TY, Lin CC, Yang PC, Wu TC, Lin DX, Zhou BS, Yu JM, Shen HB, Kubo M, Chanock SJ, Rothman N, Lan Q. Meta-analysis of genome-wide association studies identifies multiple lung cancer susceptibility loci in never-smoking Asian women. *Hum Mol Genet* 2016;25(3):620-9. (**Rank 34/289 in the category of Biochemistry & Molecular Biology**) (**Rank 16/165 in the category of Genetics & Heredity**) (**Impact factor: 5.985; 5-year impact factor: 6.353; number of citations: 0**) (**International journal, externally reviewed**) (**Percentage of contribution: 10%**) (**Co-investigator**)

37. Dai W, Zheng H, Cheung AK, Tang CS, Ko JM, Wong BW, Leong MM, Sham PC, Cheung F, Kwong DL, Ngan RK, Ng WT, Yau CC, Pan J, Peng X, Tung S, Zhang Z, Ji M, Chiang AK, Lee AW, **Lee VH**, Lam KO, Au KH, Cheng HC, Yiu HH, Lung ML. Whole-exome sequencing identifies MST1R as a genetic susceptibility gene in nasopharyngeal carcinoma. *Proc Natl Acad Sci U S A* 2016 Mar 22;113(12):3317-22. (**Rank 4/63 in the category of Multidisciplinary Sciences**) (**Impact factor: 9.243; 5-year impact factor: 10.285; number of citations: 0**) (**International journal, externally**

reviewed) (Percentage of contribution: 10%) (Co-investigator)

38. Zhang LY, Wu JL, Qiu HB, Dong SS, Zhu YH, **Lee VH**, Qin YR, Li Y, Chen J, Liu HB, Bi J, Ma S, Guan XY, Fu L. PSCA acts as a tumor suppressor by facilitating the nuclear translocation of RB1CC1 in esophageal squamous cell carcinoma. *Carcinogenesis* 2016 Mar;37(3):320-32. (**Rank 37/213 in the category of Oncology**) (**Impact factor: 4.874; 5-year impact factor: 5.368; number of citations: 0**) (**International journal, externally reviewed**) (Percentage of contribution: 10%) (Co-investigator)

39. Shen Z, Wang DD, Ma L, Yan H, Wong MP, **Lee VHF**. A computational study of three frequent mutations of EGFR and their effects on protein dimer formation and non-small cell lung cancer drug resistance. *Current Bioinformatics* 2016;11(3): 382-391. (**Rank 74/77 in the category of Biochemical Research Methods**) (**Rank 49/56 in the category of Mathematical & Computational Biology**) (**Impact factor 0.770, 5-year impact factor 0.930**) (**International journal, externally reviewed**) (Percentage of contribution: 10%) (Co-investigator)

40. Ma WH, Ng S, Ho WY, Law M, **Lee VHF**, Wong KK, Tso WK. Radiation dosimetry in selective internal radiation treatment in patients with portosystemic shunts to umbilical veins. *Hong Kong J Radiol* 2016;19:137-40. (**Impact factor 0, 5-year impact factor 0**) (**Local journal, externally reviewed**) (Percentage of contribution: 10%) (Co-investigator)

41. Zheng H, Dai W, Cheung AKL, Ko JMY, Kan R, Wong BWY, Leong MML, Deng M, Kwok TCT, Chan JYW, Kwong DLW, Lee AWM, Ng WT, Ngan RKC, Yau CC, Tung S, **Lee VHF**, Lam KO, Kwan CK, Li WS, Yau S, Chan KW, Lung ML. Whole-Exome Sequencing Identifies Multiple Novel Loss-of-Function Mutations of NF-κB Pathway Regulators in Nasopharyngeal Carcinoma. *Proc Natl Acad Sci U S A* 2016 (accepted for publication) (**Rank 4/63 in the category of Multidisciplinary Sciences**) (**Impact factor: 9.243; 5-year impact factor: 10.285; number of citations: 0**) (**International journal, externally reviewed**) (Percentage of contribution: 10%) (Co-investigator)

42. Yang L, Lam KO, **Lee VHF**, Lee AWM. Gefitinib-induced toxic epidermal necrolysis in a patient with metastatic non-small cell lung cancer. *Hong Kong J Radiol* 2016 (accepted for publication) (**Impact factor: 0; 5-year impact factor: 0; number of citations: 0**) (**Local journal, externally reviewed**) (Percentage of contribution: 30%) (Co-investigator)

43. Chai AWY, Cheung AKL, Dai W, Ko JMY, Ip JCY, Chan KW, Kwong DLW, Ng WT, Lee AWM, Ngan RKC, Yau CC, Tung SY, **Lee VHF**, Lam AKY, Law S, Lung ML. Metastasis-suppressing NID2, an epigenetically-silenced gene, in the pathogenesis of nasopharyngeal carcinoma and esophageal squamous cell carcinoma. *Oncotarget* (accepted for publication) (**Impact factor: 5.008; 5-year impact factor: 5.415; number of citations: 0**) (**International journal, externally reviewed**) (Percentage of contribution: 10%) (Co-investigator)

44. Lam KO, Lee KC, Chiu J, **Lee VHF**, Leung R, Choy TS, Yau T. The real world use of regorafenib for metastatic colorectal cancer: Multicenter analysis of treatment pattern and outcomes in Hong Kong. Postgrad Med J 2016 (accepted for publication) (**Impact factor: 1.633; 5-year impact factor: 1.709; number of citations: 0**) (**International journal, externally reviewed**) (**Percentage of contribution: 20%**) (**Co-investigator**)
45. Karam I, Yao M, Heron DE, Poon I, Koyfman SA, Yom SS, Siddiqui F, Lartigau E, Cengiz M, Yamazaki H, Hara W, Phan J, Vargo JA, **Lee V**, Foote RL, Harter KW, Lee NY, Sahgal A, Lo SS. Survey of Current Practices from the International Stereotactic Body Radiotherapy Consortium (ISBRTC) for Head and Neck Cancers. Future Oncology 2016 (published online) (**Impact factor: 2.129; 5-year impact factor: 2.592; number of citations: 0**). (**International journal, externally reviewed**) (**Percentage of contribution: 10%**) (**Co-investigator**)
46. Law WM, Wong KK, Tso WK, **Lee VHF**, Luk MY, Tong CC, Chu FSK. Personnel dose reduction in 90Y microspheres liver-directed radioembolisation: from interventional radiology suite to patient ward". Br J Radiol 2016 (submitted for publication) (**Impact factor: 1.840, 5-year impact factor: 2.045, number of citations: 0**) (**International journal, externally reviewed**) (**Percentage of contribution: 20%**) (**Co-investigator**)
47. Seow WJ, Matsuo K, Hsiung CA, Shiraishi K, Song M, Kim HN, Wong MP, Hong Y, H. Hosgood III D, Wang Z, Chang I, Wang JC, Chatterjee N, Tucker M, Wei H, Mitsudomi T, Zheng W , Kim JH, Zhou B, Caporaso NE, Albanes D, Shin MH, Chung LP, An SJ, Wang P, Zheng H, Yatabe Y, Zhang XC, Kim YT, Shu XO, Kim Y, Wu C, Bassig BA, Chang J, Ho JCM, Ji B, Kubo M, Daigo Y, Ito H, Momozawa Y, Ashikawa K, Kamatani Y, Honda T, Sakamoto H, Kunitoh H, Tsuta K, Watanabe S, Nokihara H, Miyagi Y, Nakayama H, Matsumoto S, Tsuboi M, Goto K, Yin Z, Shi J, Takahashi A, Goto A, Minamiya Y, Shimizu K, Tanaka K, Wu T, Wei F, Wong J, Matsuda F, Su J, Kim YH, Oh I, Song F, **Lee VHF**, Su W, Chen Y, Chang G, Chen K, Huang M, Yang P, Lin H, Xiang Y, Seow A, Park JY, Kweon S, Chen C, Li H, Gao Y, Wu C, Qian B, Lu D, Liu J, Jeon H, Hsiao C, Sung JS, Tsai Y, Jung YJ, Guo H, Hu Z, Wang W, Chung CC, Lawrence C, Burdett L, Yeager M, Yuenger J, Jacobs KB, Hutchinson A, Berndt SI, He X, Wu W, Wang J, Li Y, Choi JE, Park KH, Sung SW, Liu L, Kang CH, Hu L, Chen C, Yang T, Xu J, Guan P, Tan W, Wang C, Sihoe ADL, Chen Y, Choi YY, Hung J, Kim JS, Yoon H, Cai Q, Lin C, Park IK, Xu P, Dong J, Kim C, He Q, Perng R, Chen C, Vermeulen R, Wu J, Lim W, Chen K, Chan JKC, Chu M, Li Y, Li J, Chen H, Yu C, Jin L, Lo Y, Chen Y, Fraumeni Jr JF, Liu J, Yamji T, Yang Y, Wyatt K, Li SA, Dai J, Ma H, Jin G, Song B, Wang Z, Cheng S, Li X, Ren Y, Cui P, Iwasaki M, Shimazu T, Tsugane S, Zhu J, Jiang G, Fei K, Wu G, Chien L, Chen H, Su Y, Tsai F, Chen Y, Yu J, Stevens VL, Lin D, Chen K, Wu Y, Landi MT, Shen H, Rothman N, Kohno T, Chanock S J, Lan Q. Association between GWAS-identified lung adenocarcinoma susceptibility loci and EGFR mutations in never-smoking Asian women, and comparison with findings from Western populations. Nature Comm (accepted for publication) (**Impact factor: 5.985; 5-year impact factor: 6.353; number**

**(Number of citations: 0). (International journal, externally reviewed) (Percentage of contribution: 10%)
(Co-investigator)**

48. Zhang N, Fielding R, Soong I, Chan KK, Lee C, Ng A, Sze WK, Tsang J, **Lee V**, Lam WW. Psychometric assessment of the Chinese version of the brief illness perception questionnaire in breast cancer survivors. PLoS One. 2017 Mar 20;12(3):e0174093.
49. Chan OSH, **Lee VHF**, Mok TSK, Mo F, Chang ATY, Yeung RMW. The Role of Radiotherapy in Epidermal Growth Factor Receptor Mutation-positive Patients with Oligoprogression: A Matched-cohort Analysis. Clin Oncol (R Coll Radiol). 2017 (accepted for publication) (**Rank 87/213 in the category of Oncology**) (**Rank 5/25 in the category of Radiation Oncology**) (**Impact factor: 3.212; 5-year impact factor: 3.229; number of citations: 0**) (**International journal, externally reviewed**) (**Percentage of contribution: 100%**) (**Principal investigator**)
50. Chiang CL, Yeung CSY, Wong MYP, Lee VWY, **Lee VHF**, Lee FAS, Wong FCS. Emerging role of stereotactic body radiotherapy (SBRT) in the management of pancreatic cancer. HK J Radiol 2017 (accepted for publication)
51. Lai V, **Lee VHF**, Lam KO, Huang BS, Chan Q, Khong PL. Intravoxel incoherent motion MR imaging in nasopharyngeal carcinoma: Comparison and correlation with dynamic contrast enhanced MR imaging. Oncotarget 2017 (accepted for publication)
52. Yuan H, Ai Q, Kwong DLW, Fong DYT, King AD, Varut Vardhanabuti, **Lee VHF**, Khong PL. 18F-FDG PET/CT and contrast-enhanced MRI for prognostication and risk stratification of patients with nasopharyngeal carcinoma and implications on the TNM staging system. Eur J Nucl Med Mol Imag 2017
53. Zou B, **Lee VHF**, Yan H. Prediction of drug sensitivity to gefitinib/erlotinib for EGFR-mutated NSCLC based on structural interaction fingerprint and multilinear principal component analysis. BMC bioinformatics 2017 (accepted for publication)
54. Lee AWM, Tung SY, Ng WT, **Lee V**, Ngan RKC, Choi HCW, Chan LLK, Siu LL, Ng AWY, Leung TW, Yiu HHY, O'Sullivan B, Chappell R. A multicentre, phase 3, randomized trial on concurrent chemoradiotherapy plus adjuvant chemotherapy versus radiotherapy alone in patients with regionally advanced nasopharyngeal carcinoma: 10-year outcome on efficacy and toxicity. Cancer 2017 (accepted for publication)
55. Lau KS, Lam KO, Chan WL, **Lee VHF**, Kwong DLW, Leung TW. S-1 Versus S-1 plus cisplatin as first-line treatment for metastatic gastric cancer. Hong Kong J Radiol 2017;20:318-22

56. Yuan H, Ai QY, Kwong DL, Fong DY, King AD, Vardhanabhuti V, **Lee VH**, Khong PL. Cervical nodal volume for prognostication and risk stratification of patients with nasopharyngeal carcinoma, and implications on the TNM-staging system. *Sci Rep* 2017;7(1):10387.
57. You JS, Chen JP, Chan JS, **Lee HF**, Wong MK, Yeung WF, Lao LX. Effect of YH0618 soup on chemotherapy-induced toxicity in patients with cancer who have completed chemotherapy: study protocol for a randomized controlled trial. *Trials* 2016;17(1):354.
58. Chen L, Zou B, **Lee VHF**, Yan H. Analysis of the relative movements between EGFR and drug inhibitors based on molecular dynamics simulation. *Curr Bioinfomatics* 2018 (accepted for publication)
59. Ng WT, Wong ECY, **Lee VHF**, Chan JYW, Lee AWM. Head and neck cancer in Hong Kong. *Jpn J Clin Oncol*. 2017 Nov 14:1-9. doi: 10.1093/jjco/hyx151.
60. Lai V, **Lee VHF**, Lam KO, Huang B, Chan Q, Khong PL. Intravoxel incoherent motion MR imaging in nasopharyngeal carcinoma: comparison and correlation with dynamic contrast enhanced MR imaging. *Oncotarget* 2017;8(40):68472-68482.
61. Chan MFT, Lam QYN, **Lee VHF**, Ho PPY, Sze HCK, Siu SWK, Kwong PWK, Leung TW. Using the Roach formula to stratify patients with localised prostate cancer treated with intensity-modulated radiotherapy. *Hong Kong J Radiol* 2017;20:103-9.
62. So TH, **Lee VHF**, Lam KO. Aflibercept-induced nephrotic syndrome. *Hong Kong J Radiol* 2017;20:146-8
63. Cheung TT, Kwok PCH, Chan S, Cheung CC, Lee AS, **Lee V**, Cheng HC, Chia NH, Chong CCN, Lai TW, Law ALY, Luk MY, Tong CC, Yau CC. Hong Kong consensus statements for the management of unresectable hepatocellular carcinoma. *Liver Cancer* 2018 (in press).
64. Au KH, Ngan RKC, Ng AWY, Poon DMC, Ng WT, Yuen KT, **Lee VHF**, Tung SY, Chan ATC, Henry CK Sze HCK, Cheng ACK, Lee AWM, Kwong DLW, Anthony HP Tam AHP. Treatment Outcomes of Nasopharyngeal carcinoma in modern era after Intensity Modulated Radiotherapy (IMRT) in Hong Kong: A report of 3328 patients (HKNPCSG 1301 study) *Oral Oncol* 2018;77:16-21.

1. **Lee V.H.F. (presenting author)**, Kwong D.L.W., Khong P.L., Chua D.T.T., Ng C.Y., Wong K.W., Chan K.S., Leung T.W. and Au G.K.H., Co-registration and Application of Positron Emission Tomography (PET), Computed Tomography (CT) as compared with Magnetic Resonance Imaging (MRI) in Target Localization for Undifferentiated Carcinoma of the Nasopharynx (NPC), Hong Kong International Cancer Congress 2008. Hong Kong, Hong Kong International Cancer Congress.
2. Ng C.Y. and **Lee V.H.F.**, Feasibility Study of LINAC Based Intensity Modulated Total Marrow Irradiation for Paediatric Patients, Hong Kong International Cancer Congress 2008. Hong Kong, Hong Kong International Cancer Congress.
3. **Lee V.H.F. (presenting author)**, Ng C.Y., Chua D.T.T., Kwong D.L.W., Leung T.W. and Au G.K.H., Dosimetric Predictors of Radiation-induced Acute Nausea and Vomiting in Intensity Modulated Radiation Therapy for Undifferentiated Carcinoma of the Nasopharynx, 10th Biennial ESTRO Conference on Physics and Radiation Technology for Clinical Radiotherapy 2009.
4. **Lee V.H.F. (presenting author)**, Ng C.Y., Liu K.Y., Law W.L., Ho J.W.C., Chua D.T.T., Kwong D.L.W., Choy T.S., Leung T.W. and Au G.K.H., Dosimetric Analysis of Pre-operative and Post-operative Concurrent Chemotherapy with Conformal Radiotherapy Delivered by 5 or 6 Beams for Rectal Cancer, Hong Kong College of Radiologists. Hong Kong, Hong Kong College of Radiologists, 2009.
5. **Lee V.H.F. (presenting author)**, Ng C.Y., Chua D.T.T., Kwong D.L.W., Khong P.L., Ng T.M.C., Leung T.W. and Au G.K.H., Shrinkage of Volumes of Parotid and Submandibular Glands but Elevated Radiation Doses during Intensity Modulated Radiation Therapy (IMRT) for Nasopharyngeal Carcinoma., Hong Kong International Cancer Congress. Hong Kong, 16th Hong Kong International Cancer Congress, 2009.
6. Ng C.Y. and **Lee V.H.F.**, Comparing the sensitivity of ionization chamber array to film and point dose measurement for IMRT delivery errors, 2009 The American Association for Physicists in Medicine (AAPM) Annual Meeting and Exhibition. 2009. <http://dx.doi.org/10.1118/1.3181702>
7. Ng C.Y., **Lee V.H.F.**, Kwong D.L.W., Law M.L. and Wu P.M., Comparing the Sensitivity of Ionization Chamber Array to Film + Point Dose Measurement to IMRT Delivery Errors, The American Association of Physicists in Medicine (AAPM). AAPM, 2009.
8. Tsang J.W.H., Lau T.T.S., Lee V.K.H., Yung S.T., Li V.W.K., Cheung T.K., Lam W.W.T., **Lee V.H.F.**, Au G.K.H. and Kwong D.L.W., Higher Education And Younger Age Are Associated With Better Understanding Of Clinical Trials Among Hong Kong Cancer Patients, 16th Hong Kong International Cancer Congress & 6th Annual Meeting Centre For Cancer Research. 2009.

9. **Lee V.H.F. (presenting author)**, Kwong D.L.W., Khong P.L., Chua D.T.T., Ng C.Y., Wong G.K.W., Chan K.S., Leung T.W. and Au G.K.H., Co-registration and application of positron emission tomography (PET), computed tomography (CT) as compared with magnetic resonance imaging (MRI) in target localization for undifferentiated carcinoma of the nasopharynx (NPC), ASTRO 2009 Annual Meeting, Chicago, USA, 1-5 November 2009.
10. **Lee V.H.F. (presenting author)**, Hung K.N., Chua D.T.T., Kwong D.L.W., Leung T.W. and Au G.K.H., Evaluation of Three Stratification Systems Predicting Recurrence and Prognosis in Patients with Brain Metastases after Tumour Removal and Whole-brain Irradiation. American Society of Clinical Oncology. USA, ASCO, American Society of Clinical Oncology (ASCO), 2010.
11. Chau J., Tse V.C., Ng W.T., **Lee V.H.F.**, Lee A.W.M., Chua D.T.T. and McGhee S., Cost-analysis of XELOX and FOLFOX4 for treatment of colorectal cancer in Hong Kong (abstract), 7th Annual Conference Organisation for Oncology and Translational Research, 13-14 May 2011, Hong Kong. Hong Kong, Organisation for Oncology and Translational Research, 2011, 46. <http://dx.doi.org/10.1186/1471-2407-11-288>
12. **Lee V.H.F. (presenting author)**, Ng C.Y., Chua D.T.T., Kwong D.L.W., Ng T.M.C., Leung T.W. and Au G.K.H., Shrinkage of Volumes of Parotid and Submandibular Glands but Elevated Radiation Doses during Intensity Modulated Radiation Therapy (IMRT) for Nasopharyngeal Carcinoma., 4th World Congress of International Federation of Head and Neck Oncologic Societies 2010. Seoul, South Korea, International Federation of Head and Neck Oncologic Societie.
13. **Lee V.H.F. (presenting author)**, Kwong D.L.W., Khong P.L., Chua D.T.T., Ng C.Y., Wong G.K.W., Chan K.S., Leung T.W. and Au G.K.H., The optimal window-setting of Positron Emission Tomography when co-registered with Computed Tomography (CT) and Magnetic Resonance Imaging (MRI) in Target Localization For Undifferentiated Carcinoma of the Nasopharynx (NPC). European Society of Therapeutic Radiology and Oncology. The Netherlands, ESTRO, European Society of Therapeutic Radiology and Oncology, 2010.
14. **Lee V (presenting author)**, Kwong DLW, Ng SCY, Leung TW, Au GKH. Impact of intravenous contrast used in computed tomography (CT) scan of dose to the carotids and thyroid in IMRT planning for nasopharyngeal carcinoma. ASTRO 52nd Annual Meeting 2010.
15. **Lee V.H.F. (presenting author)**, Ng C.Y., Chua D.T.T., Kwong D.L.W., Khong P.L., Ng M.C., Leung T.W. and Au G.K.H., Shrinkage of Volumes of Parotid and Submandibular Glands but Elevated Radiation Doses during Intensity Modulated Radiation Therapy (IMRT) for Nasopharyngeal Carcinoma, ASTRO 2011 Annual Meeting. 2011.
16. **Lee V.H.F. (presenting author)**, Chan A.S.Y., Choy T.S., Tsang J.W.H., Leung T.W., Au G.K.H.

and Kwong D.L.W., Comparative analysis of sequence of chemotherapy and targeted therapy for non-small cell lung cancer, Roche Asia Oncology Forum 2010. 2011.

17. Leung CH, CJ Seneviratne CJ, **Lee HF**, Wong SSW, Samaranayake LP. Host-pathogen attributes of oral candidiasis in nasopharyngeal carcinoma patients. Abstract presentation at the Annual Scientific Sessions, International Association for Dental Research, South East Asia Division, Singapore, October, 2011. This project won the IADR/SEA Joseph Lister Award for Oral Disease Prevention.
18. Taw B.T., **Lee V.H.F.**, Hung K.N., Ng C.Y. and Lui W.M., The efficacy and safety of LINAC stereotactic radiosurgery booster after whole brain radiotherapy for cerebral metastases , XXth ESSFN conference in 2011.
19. **Lee V.H.F. (presenting author)**, Tsang J.W.H., Luk M.Y., Kwong W.K.P., Leung T.W. and Kwong D.L.W., Comparative analysis of efficacy of pegfilgrastim vs filgrastim for patients with soft tissue sarcoma and testicular germ cell tumour receiving potent cytotoxic chemotherapy., 19th Annual Scientific Meeting of the Hong Kong College of Radiologists. 2011.
20. **Lee V.H.F. (presenting author)**, Ng C.Y., Ng M.C., Ho P.P.Y., Leung T.W. and Kwong D.L.W., Change in Volumes and Radiation Doses of Parotid and Submandibular Glands during Intensity Modulated Radiation Therapy (IMRT) for Nasopharyngeal Carcinoma., American Society for Radiation Oncology. 2011. <http://dx.doi.org/10.1016/j.ijrobp.2011.06.1041>
21. Chua D.T.T., Ho P., **Lee V.H.F.** and Sham J.S.T., A Randomized Phase II Study of External Beam Reirradiation versus External Beam Reirradiation Plus Radiosurgery Boost in Recurrent Nasopharyngeal Carcinoma, ASTRO's 53rd Annual Meeting. USA, American Society for Radiation Oncology, 2011, 81(2 Suppl): S506.
22. Lam K.O., **Lee V.H.F.**, Choi C.W., Liu K.Y., Leung T.W. and Kwong D.L.W., Bevacizumab After Cetuximab Failure In Kras Wild-type Metastatic Colorectal Carcinoma (Abstract), Annals of Oncology. UK, Oxford University Press, 2012, 23; suppl 4: iv100; P-0248. <http://dx.doi.org/10.1093/annonc/mds153>
23. Lam K.O. and **Lee V.H.F.**, Kras Wild-Type Metastatic Colorectal Cancer Treated with Cetuximab at First-Line, Merch Oncology Summit 2012.
24. Lam K.O., Lau K.S., Ho P.Y., **Lee V.H.F.**, Choy T.S., Liu R.K.Y., Kwong D.L.W. and Leung T.W., Safety and efficacy of cetuximab-XELOX combination in the first-line treatment of Kras wild-type metastatic colorectal cancer-QMH experience, Annual Scientific Meeting 2012, Hong Kong College of Radiologists. Hong Kong College of Radiologists, 2012.

25. Chan W.L., **Lee V.H.F.**, Ho P.P.Y., Leung D.K.C., Wong L.S., Siu W.K.S., Liu K.Y. and Leung T.W., Biweekly cetuximab and first-line chemotherapy in Chinese patients with K-RAS wild-type coloectal cancers, Hong Kong College of Radiologists 20th Annual Scientific Meeting. Hong Kong, Hong Kong College of Radiologists, 2012.
26. Chan W.L., Siu W.K.S., **Lee V.H.F.** and Leung T.W., Multi-modality Treatment Achieving Long-term Control for Inoperable Adenoid Cystic Carcinoma of Trachea: A Case Report with Review of Medical Literature, Hong Kong College of Radiologists 20th Annual Scientific Meeting. Hong Kong, Hong Kong College of Radiologists, 2012.
27. Chan W.L., **Lee V.H.F.**, Choy T.S., Ho P.P.Y., Leung D.K.C., Wong L.S., Lam K.O., Kwong D.L.W. and Leung T.W., Predictors of Treatment Outcome in Patients Treated with Radical Chemoradiotherapy For Stage III Non-Small Cell Lung Cancer , Hong Kong College of Radiologists 20th Annual Scientific Meeting. Hong Kong, Hong Kong College of Radiologists, 2012.
28. Wong C.S. Gong N., Chu YC., Anthony M., Chan Q., Lee V.H.F., Chu K.M. and Khong P.L., Correlation of measurements from diffusion weighted MR imaging and FDG PET/CT in GIST patients: ADC versus SUV., Hong Kong College of Radiologists 20th Annual Scientific Meeting. Hong Kong, Hong Kong College of Radiologists, 2012.
29. Fang W.J., Xu N., Lam K.O., Ng S., Choi C.W., Kwong D.L.W., Zheng S.S. and **Lee V.H.F. (corresponding author)**, Comparison of Volumetric Evaluation for Tumor Response with RECIST for Metastatic Colorectal Cancer with Liver Metastases Only, Asian Oncology Summit 2012.
30. Geater S.L., Ianotti N., Thongprasert S., Spira A., Smith D., **Lee V.H.F.**, Lim W.T., Gopalakrishna P., Reynolds C. and Mok T.S.K., Phase II Study of Two Eribulin Regimens in Combination with Erlotinib in Patients (PTS) with Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) , 37th ESMO Congress 2012. Austria, European Society of Medical Oncology, 23 (suppl 9): ix389-ix399 1205P. <http://dx.doi.org/10.1093/annonc/mds408>
31. Ho P., Chua D.T.T., Wong L.S., **Lee V.H.F.** and Leung T.W., Efficacy and Toxicity of Reirradiation using Intensity Modulated Radiotherapy for Recurrent or Second Primary Nasopharyngeal Carcinoma, ASTRO's 53rd Annual Meeting. USA, American Society for Radiation Oncology, 2012, 81(2 Suppl): S507.
32. Chua D.T.T., **Lee V.H.F.**, Tsang J.W.H., Ng C.Y., Leung T.W. and Au G.K.H., Re-treatment of Nasopharyngeal Carcinoma by Sequential Chemo-radiotherapy with or without Cetuximab , ASTRO's 51st Annual Meeting. USA, American Society for Radiation Oncology, 2012, 75(3 Suppl): S423-S424.
33. **Lee V.H.F. (presenting author)**, Fang W.J., Lam K.O., Choi C.W., Ng S., Ho G., Cheng T., Liu

K.Y., Leung T.W., Kwong D.L.W. and Zheng S.S., Addition of Cetuximab to Oxaliplatin-based chemotherapy on Liver and Spleen Size and Thrombocytopenia in Patients with Metastatic Colorectal Cancer (Abstract), Annals of Oncology. UK, Oxford University Press, 2012, 23: suppl 4: iv94; P-0224. <http://dx.doi.org/10.1093/annonc/mds153>

34. Lee V.W.Y. and **Lee V.H.F.**, Comparative effectiveness and cost-effectiveness assessment in erlotinib vs. gefitinib first-line treatment of EGFR activating mutation positive non-small cell lung cancer for Hong Kong, ISPOR 5th Asia-Pacific Conference. Taiwan, ISPOR, 2012
35. Mok T., Wu Y.L., Thongprasert S., Yu C.L., Zhang L., Ladrera G.E., Srimuninnimit V., Sriuranpong V., Sandoval-Tan J., Zhu Y., Liao M., Zhou C., Pan H., **Lee V.H.F.**, Chen Y.M., Sun Y., Margono B., Jin K., Truman M. and Lee J.S., A randomized placebo-controlled phase III study of intercalated erlotinib with gemcitabine/platinum in first-line advanced non-small cell lung cancer (NSCLC): FASTACT-II, ASCO Annual Meeting 2012. USA, Americal Society of Clinical Oncology, 30(15_suppl (May 20 Supplement)): 7519.
36. Ng C.Y., **Lee V.H.F.** and Leung T.W., Dosimetric Evaluation of the Interplay between LINAC Movement and Tumor Motion in Respiratory Gated VMAT of Lung Cancer, American Society for Radiation Oncology 54th Annual Meeting. 2012. <http://dx.doi.org/10.1016/j.ijrobp.2012.07.2051>
37. Lau Y.M., Leung J.K.C. and **Lee V.H.F. (corresponding author)**, The PBL Experiences in Scientific & Health Education at University Level with English as a Second Language, ICERI 2012 - 5th International Conference of Education Research and Innovation. Spain, ICERI, 2012, ICERI2012 Proceedings: 2461.
38. Ng C.Y., **Lee V.H.F.**, Liu K.Y., Law W.M., Ma W.H., Tso W.K., Leung T.W. and Khong P.L., 3 Dimensional Dosimetry for 90Y Selective Internal Radiation Treatment Based on 90Y PET Imaging, Hong Kong College of Radiologists 20th Annual Scientific Meeting. Hong Kong, Hong Kong College of Radiologists, 2012.
39. Szeto C.Y.Y., Kwong D.L.W., Lee A., Ng W.T., **Lee V.H.F.** and Lung M.L., Evaluation of micro-RNA biomarker panel on biopsies and non-invasive samples in nasopharyngeal carcinoma, Poster at 103rd Annual Meeting of American Association of Cancer Research, Chicago, USA. 2012.
40. Wong S.W.S., Seneviratne C.J. and **Lee V.H.F.**, Host-pathogen attributes of oral candidiasis in nasopharyngeal carcinoma patients., Annual Scientific Sessions, International Association for Dental Research, South East Asia Division,Singapore 2012.
41. Ye M., Lam W.W.T., Tsang J.W.H., **Lee V.H.F.**, Soong I., Chan K.K.L., Lee C., Sze W.K., Ng A., Yeo W., Suen J., Ho W.M. and Fielding R., Symptom clusters in cancer survivors in Hong Kong - a

cluster analysis (abstract), 19th Hong Kong International Cancer Congress, 8-9 November 2012, Hong Kong. Hong Kong, LKS Faculty of Medicine, HKU, 2012, A72.

42. Ye M., Lam W.W.T., Tsang J.W.H., **Lee V.H.F.**, Soong I., Chan K.K.L., Lee C., Sze W.K., Yeo W., Suen J., Ho W.M. and Fielding R., Symptom clustering in different groups of cancer survivors (abstract and powerpoint presentation), The third Meeting of East Asian Psycho-Oncology Network (EAPON), 6-7 September 2012, Beijing. Beijing, Peking University, 2012, 18-19.

43. **Lee V.H.F. (presenting author)**, Fang W.J., Lam K.O., Choi C.W., Ng C.Y., Ho G.C.L., Cheng T.K.C., Liu K.Y., Leung T.W., Kwong D.L.W. and Zheng S.S., Capecitabine but not 5-FU worsened hepatosplenomegaly and liver function when used with oxaliplatin and cetuximab as first-line treatment in K-ras wild-type metastatic colorectal cancer , ASCO Annual Meeting 2013. USA, American Society of Clinical Oncology.

44. Chan W.L., Ng C.Y., Law W.M., **Lee V.H.F.**, Wan K.Y. and Leung T.W., Volumetric-modulated Arc Therapy in Differentiated Thyroid Cancer: a comparison with Intensity-modulated Radiotherapy, World Congress of Thyroid Cancer 2013. Toronto, World Congress of Thyroid Cancer.

45. Lai V., Li X., **Lee V.H.F.**, Lam K.O., Chan Q. and Khong P.L., Use of Intravoxel Incoherent Motion Magnetic Resonance Imaging In Differentiation Between Recurrent Nasopharyngeal Carcinoma and Post-chemoradiation Fibrosis: Initial Experience. , 6th International Symposium of Nasopharyngeal Carcinoma 2013.

46. Lam K.O., **Lee V.H.F.**, Choi C.W., Sze C.K.H., Kwok R.C.C., Shum B.C.Y., Wong I.W.C., Tsang J.W.H., Liu K.Y., Leung T.W. and Kwong D.L.W., Cetuximab beyond progression in Kras wild-type metastatic colorectal cancer, In: Annals of Oncology, ESMO 15th World Congress on Gastrointestinal Cancer. Annals of Oncology, 2013, 24; Suppl. 4. <http://dx.doi.org/doi:10.1093/annonc/mdt203.252>

47. Lai V., **Lee V.H.F.**, Lam K.O., Sze C.K.H., Huang B. and Khong P.L., Utility of Intravoxel Incoherent Motion MR Imaging in Characterisation of Nasopharyngeal Carcinoma, Nasopharyngeal Carcinoma AoE IAB. 2013.

48. Lam K.O., Ho P.Y., Lau K.S., **Lee V.H.F.**, Liu K.Y., Leung T.W. and Kwong D.L.W., Treatment outcomes and implication of complete response on PET scan after first-line cetuximab-xelox in Chinese patients with Kras wild-type metastatic colorectal cancer, APAC-NECTAR Merck Serono Oncology Summit 2013.

49. Chan W.L., **Lee V.H.F.**, Choy T.S. and Leung T.W., Pineal Parenchymal Tumor of Intermediate Differentiation: two cases treated with adjuvant radiotherapy, 20th Hong Kong International Cancer Congress. Hong Kong, Li Ka Shing Faculty of Medicine, The University of Hong Kong, 2013.

50. **Lee V.H.F. (presenting author)**, Kwong D.L.W., Lam K.O., Leung D.K.C., Ho P.P.Y., Cheung Y.T., Wong S.Y., Tsang J.W.H. and Leung T.W., Pre-treatment EBV DNA differentiates different stages of undifferentiated carcinoma of the nasopharynx, European Cancer Congress 2013. Amsterdam, European Cancer Organisation.
51. **Lee V.H.F. (presenting author)**, Ng C.Y., Taw B.T.B., Hung K.N., Lam K.O., Chan W.W.L., Leung D.K.C., Ho P.P.Y., Sze C.K.H., Leung T.W. and Kwong D.L.W., Whole-brain Radiotherapy with Simultaneous Integrated Boost Using Volumetric Modulated Arc Therapy (VMAT) for Patients of Recursive Partitioning Analysis (RPA) Class I and II Suffering from 1-3 Brain Metastases, Hong Kong College of Radiologists 21st Annual Scientific Meeting. Hong Kong, Hong Kong College of Radiologists, 2013.
52. Leung D.K.C., **Lee V.H.F.**, Liu K.Y., Luk M.Y., Law W.M., Tso W.K., Wong K.K., Wong K.K., Ma V.W.H., Ng C.Y., Poon R.T.P., Tong C.C. and Leung T.W., Radioembolization with yttrium-90 microspheres for inoperable advanced hepatocellular carcinoma (HCC), Hong Kong College of Radiologists 21st Annual Scientific Meeting. Hong Kong, Hong Kong College of Radiologists, 2013.
53. **Lee V.H. (presenting author)**, Kwong D.L.W., Lam K.O., Sze H.C.K., Ho P.P.Y., Chan W.L., Leung D.K.C., Wong L.S., Leung T.W.. Comparison of post-treatment plasma EBV DNA with nasopharyngeal biopsy in patients after radical (chemo)radiotherapy for non-metastatic nasopharyngeal cancer. (Oral presentation at American Society for Radiation Oncology (ASTRO) 56th Annual Meeting, to be held in San Francisco in September 2014.)
54. Hui E.P., Ma B., Chan A.K.C., Chan C.M.L., Wong C.S.C., To K.F., Chan A.W.H., Tung S.Y., Ng W.T., Cheng A.C.K., **Lee V.H.F.**, Chan S.L., Loong H.H.F., Kam M.K.M., Leung S.F., Ho R., Mo F., Lo D.Y.M., Ngan R.K.C., Chan A.T.C.. Single nucleotide polymorphism (SNP) of excision repair cross complementation group (ERCC1) in nasopharynx cancer (NPC): A companion biomarker study to Hong Kong NPC Study Group 0502 trial. (Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 2014 from 30 May to 3 June 2014 in Chicago, USA)
55. **Lee V.H.F. (presenting author)**, Liu R.K.Y., Luk M.Y., Tong C.C., Law W.M., Leung D.K.C., Tso W.K., Ma V.W.H., Leung T.W., Kwong D.L.W., Poon R.T.P.. Treatment outcomes of extremely advanced inoperable hepatocellular carcinoma treated with yttrium-90 radioembolization. (Presented at ESMO 16th World Congress on Gastrointestinal Cancer, from 25 June to 28 June 2014 in Barcelona, Spain)
56. Lam K.O., Cheung G, Sze H.C.K., **Lee V.H.**, Tsang J, Choy T.S., Leung T.W., Kwong D.L.W. The impact of complete metabolic response in the treatment of metastatic colorectal cancer (Presented at ESMO 16th World Congress on Gastrointestinal Cancer, from 25 June to 28 June 2014 in Barcelona,

Spain)

57. Kwong D.L.W., **Lee V.H.**, Khong P.L.. Early response assessment by PET scan in chemoradiotherapy for nasopharyngeal carcinoma. (Presented at the 39th Congress of the European Society for Medical Oncology (ESMO 2014), from 26-30 September 2014, Madrid, Spain)
58. Lau S.S.N., Taw B.B.T., **Lee V.H.F.**, Hung K.N., Lui W.M.. X-knife stereotactic radiosurgery for cerebral AVM: Queen Mary Hospital experience. (Oral presentation at the 21st Annual Scientific Meeting of the Hong Kong Neurosurgical Society, Hong Kong, 5-6 December 2014.
59. Law M.W.W., Wong K.K., Tso W.K., **Lee V.H.F.**, Luk M.Y.. Personnel dose reduction for Y90 microspheres liver-directed radioembolisation: from angiogram suite to patient ward. (Presented as Oral Presentation at European Congress of Radiology from 4 to 8 March 2015 in Vienna, Austria)
60. Wong S.S.W., Fong H.L., Seneviratne C.J., **Lee V.H.F.**, Samaranayake L.P.. Drug-resistant poly-fungal oral species in nasopharyngeal carcinoma patients. Presented at International Association for Dental Research Annual Meeting in Boston 2015
61. Seneviratne C.J., Fong H.L., Wong S.S.W., **Lee V.**, Samaranayake L.P.. Salivary biomarkers and microbial attributes in oral health of nasopharyngeal-carcinoma. Presented at International Association for Dental Research Annual Meeting in Boston 2015
62. Ho P.P.Y., **Lee V.H.F.**, Chan W.L., Leung T.W.. Prescription compliance of prn symptom control medications for terminal cancer patients in an oncology centre in Hong Kong. (Accepted for poster presentation at 11th Asia Pacific Hospice Conference from 30 April to 3 May 2015 in Taipei, Taiwan)
63. Chan W.L., Ng C.W., Lee C, Cheng P, Cheung K.W., Siu S.W.K., **Lee V.H.F.**, Leung T.W. Effective Management of Breathlessness in Advanced Cancer Patient with a Program-based, Multi-disciplinary Approach: SOB Program in Hong Kong. Presented at the 14th World Congress of the European Association for Palliative Care, from 8 to 10 May 2015, Copenhagen, Demark.
64. **Lee V.H.F. (presenting author)**, Seneviratne C.J., Fong H.L., Wong S.S.W., Kwong D.L.W., Lam K.O., Leung T.W., Samaranayake L.P.. Prospective study on oral candidial infection after intensity-modulated radiation therapy for non-metastatic nasopharyngeal carcinoma: correlation with the radiation dose to the parotids. **Presented as Oral Presentation at 6th Congress of European Microbiologists in the Netherlands in June 2015.**
65. **Lee V.H.F. (presenting author)**, Kwong D.L.W., Leung T.W., Choi C.W., Ng S.C.Y., Lam K.O., Sze C.K., Tong C.C., Ho P.P.Y., Chan W.W.L., Wong L.S., Leung D.K.C., Chan A.S.Y., Chan F.T., Lau K.S.. Serial early post-intensity-modulated radiation therapy (IMRT) undetectable plasma EBV DNA to predict long-term outcomes in nasopharyngeal cancer (NPC). **Presented as Oral Presentation at 2015 ASCO Annual Meeting on 29 May to 2 June, 2015**

66. **Lee V.H.F. (presenting author)**, Sze H.C.K., Lam K.O., Kwong D.L.W., Leung T.W. Use of PET-CT scan as tool of treatment response evaluation for solitary spine metastasis after SBRT. Presented as poster presentation at 12th International Stereotactic Radiosurgery Society Congress in Yokohama, Japan in June 2015
67. Kwong D.L.W., **Lee V.H.F.**, Lam K.O., Wong G.K.W., Khong P.L. Biological tumor volume (BTM) as a predictor for local control in nasopharyngeal carcinoma (NPC). Presented as poster presentation at 2015 ASCO Annual Meeting on 29 May to 2 June, 2015
68. **Lee V.H.F. (presenting author)**, Kwong D.L.W., Ng S.C.Y., Lam K.O., Sze H.C.K., Ho P.P.Y., Chan W.W.L., Wong L.S., Leung D.K.C., Chan S.Y., Chan F.T., Lau K.S., Leung T.W.. Comparison of hyperfractionated (HF) to conventionally fractionated (CF) salvage IMRT for locoregionally advanced recurrent nasopharyngeal carcinoma (NPC). Presented as poster presentation at ASTRO 56th Annual Meeting in October 2015
69. Lam K.O., Lee K.C., **Lee V.H.F.**, Yau T. Regorafenib for metastatic colorectal cancer in community setting: a multicenter retrospective analysis in Hong Kong. Presented as poster presentation at ESMO 17th World Congress on Gastrointestinal Cancer, from 1 July to 4 July 2015 in Barcelona, Spain
70. Chan SY, **Lee VHF**, Kwong DLW, Lam KO, Tong CC, Sze CK, Ng SCY, Leung TW, AWM Lee. Hypothyroidism after radical intensity-modulated radiation therapy for nasopharyngeal carcinoma: an investigation of dosimetric predictors. Presented as oral presentation at 23rd Annual Scientific Meeting, Hong Kong College of Radiologists, November 2015.
71. Lau KS, Choy TS, **Lee VHF**, Leung DKC, Leung TW. Treatment outcomes of patients with early-stage lung cancer or pulmonary oligometastases treated with stereotactic body radiation therapy. Presented as oral presentation at 23rd Annual Scientific Meeting, Hong Kong College of Radiologists, November 2015
72. **Lee VHF (presenting author)**, Chan SY, Kwong DLW, Lam KO, Tong CC, Sze CK, Ng SCY, Leung TW, AWM Lee. Dosimetric Predictors of Hypothyroidism After Radical Intensity-modulated Radiation Therapy for Nasopharyngeal Carcinoma. Presented as poster presentation at ASTRO 2016 Multidisciplinary Head and Neck Cancer Symposium (February 18-20, 2016), The United States of America.
73. Ho P.P.Y, **Lee VHF**, Yuen KK, Chan WL, Choy TS, Lee AWM, Leung TW. Factors correlating with shorter survival after treatment: Aiding oncologists to choose who (not) to receive palliative systemic therapy. Presented as poster presentation at ASCO 2016 Annual Meeting (June 3-7, 2016), The United States of America.

74. **Lee V (presenting author)**, Lam T, Ng S, Szeto M, Lam K, Leung T. Effect of Titanium Hardware on Radiation Dosimetry in Post-operative Proton vs. Photon Spinal Stereotactic Body Radiation Therapy After Surgical Decompression for Spinal Cord Compression. Accepted as poster presentation at ASTRO 2016 Annual Meeting (September 25-28, 2016), Boston, The United States of America.
75. **Lee VHF (presenting author)**, Kwong DLW, Lai YC, Li Y, Lam KO, Ho PPY, Chan WL, Wong LS, Leung DKC, Chan SY, Leung TW, Lee AWM. Metronomic oral cyclophosphamide as 3rd line systemic treatment or beyond in patients with inoperable locoregionally advanced recurrent or metastatic nasopharyngeal carcinoma. Accepted for poster presentation at ESMO 2016 Congress, October 7-11, 2016, Copenhagen, Denmark.
76. Siu LL, **Lee V**, Ngan R, To KF, Ahn MJ, Ng QS, Hong RL, Lin JC, Swaby RF, Cheng J, Saraf S, Chan AT. Pembrolizumab (MK-3475) vs Standard of Care Chemotherapy in Platinum Pretreated, Recurrent or Metastatic Nasopharyngeal Cancer: the Phase 2 KEYNOTE-122 Study. Presented as poster presentation at American Head and Neck Society 9th International Conference of Head and Neck Cancer (July 16-20 2016), Seattle, The United States of America.
77. Spreafico A, **Lee V**, Ngan RKC, To KF, Ahn AJ, Ng QS, Hong RL, Lin JC, Ramona F, Swaby RF, Gause C, Saraf S, Chan ATC. KEYNOTE-122: phase 2 study of pembrolizumab versus standard-of-care chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal carcinoma. Presented as poster presentation at ESMO Symposium on Immuno-Oncology 2016 (November 4-6, 2016), Lausanne, Switzerland.
78. Spreafico A, **Lee V**, Ngan RKC, To KF, Ahn AJ, Ng QS, Hong RL, Lin JC, Ramona F, Swaby RF, Gause C, Saraf S, Chan ATC. KEYNOTE-122: phase 2 study of pembrolizumab versus standard-of-care chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal carcinoma. Presented as poster presentation at Society for Immunotherapy of Cancer (November 9-13, 2016), National Harbour, Maryland, The United States of America.
79. Spreafico A, **Lee V**, Ngan RKC, To KF, Ahn AJ, Ng QS, Hong RL, Lin JC, Ramona F, Swaby RF, Gause C, Saraf S, Chan ATC. KEYNOTE-122: phase 2 study of pembrolizumab versus standard-of-care chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal carcinoma. Presented as poster presentation at ESMO Asia 2016 Congress (December 16-19, 2016), Singapore.

(4) Editorship, invited lectures and keynote speeches (Total 52)

(A) International conferences (Total 17)

1. **Lee V.H.F.**, Radiotherapy for Head and Neck Cancer – Principles and Techniques, Symposium on Head and Neck Tumours and Reconstruction, Ministry of Health, Hospital Kuala Lumpur, Malaysia.

Malaysia, Ministry of Health, Hospital Kuala Lumpur, Malaysia, 2009.

2. **Lee V.H.F.**, Management of Cancers of the Retromolar Trigone, Oropharynx and Tonsils- an oncologist's perspective, Symposium on Head and Neck Tumours and Reconstruction, Ministry of Health, Hospital Kuala Lumpur, Malaysia. Malaysia, Ministry of Health, Hospital Kuala Lumpur, Malaysia, 2009.
3. **Lee V.H.F.**, Case Sharing Session on lung cancer, Asia Pacific Lung Conference 2010.
4. **Lee V.H.F.**, Palliative chemotherapy and radiotherapy for lung cancer, Annual Scientific Meeting, Macau Chest Diseases and Tuberculosis Association. 2011.
5. **Lee V.H.F.**, New finding of predictor of radiation nausea/vomiting for patients with nasopharyngeal carcinoma treated with Intensity Modulated Radiation Therapy, 5 April 2012, Invited lecture by Department of Radiation Oncology, First Affiliated Hospital, Zhejiang University, Hangzhou, Zhejiang Province, People's Republic of China. People's Republic of China, Department of Clinical Oncology, The University of Hong Kong, 2012.
6. **Lee V.H.F.**, Clinical Experience Sharing on the use of anti-VEGF therapy for non-small cell lung cancer, August 2012, Macau Chest Diseases and Tuberculosis Association. Macau, Macau Chest Diseases and Tuberculosis Association, 2012.
7. **Lee V.H.F.**, Selective Internal Radiation Therapy (SIRT) - Emerging Role in Liver Cancer Treatment, Selective Internal Radiation Therapy (SIRT) - Emerging Role in Liver Cancer Treatment, April 2013. Singapore, Singapore General Hospital, 2013.
8. **Lee V.H.F.**, 12 October 2013, Annual General Meeting 2013, Palliative and Maintenance Therapy for Metastatic Non-small-cell Lung Cancer. Macau, Macau Chest Diseases and Tuberculosis Association, 2013.
9. **Lee V.H.F.** Palliative chemotherapy and targeted therapy for recurrent/metastatic nasopharyngeal carcinoma. 5th World Congress – International Federation of Head and Neck Oncological Societies (IFHNOS) and American Head and Neck Society (AHNS) 2014 Annual Meeting, New York, USA, 26-30 July, 2014.
10. **Lee V.H.F.** Does Head and Neck Mucosal Melanoma Resembles the Cutaneous Type? Tri-Society Head and Neck Oncology Meeting, Darwin, Australia, 13-17 August, 2014.
11. **Lee V.H.F.** Palliative chemotherapy and targeted therapy for recurrent/metastatic nasopharyngeal carcinoma. Tri-Society Head and Neck Oncology Meeting, Darwin, Australia, 13-17 August, 2014.

12. **Lee V.H.F.** Recent advances in the treatment of melanoma and non-small cell lung cancer. Macau Oncology Association Meeting, 6th March 2015, Macau.
13. **Lee V.H.F.** Advances of Radiation Therapy for Lung Cancer. Delivered in Annual Scientific Meeting of Macau Chest Diseases and Tuberculosis Association, 13th September 2015, Macau.
14. **Lee V.H.F.** Cancer Database Experience from Queen Mary Hospital. Delivered in Department of Clinical Oncology, Queen Mary Hospital, Hong Kong, organised by China Association of Health Promotion and Education 中國健康教育與促進協會 and Department of Clinical Oncology, The University of Hong Kong, 31st October 2015.
15. **Lee V.H.F.** Anti-cancer Treatment for Neuroendocrine Tumours. Delivered in 6th Joint Scientific Meeting of Royal College of Radiologists & Hong Kong College of Radiologists and 23rd Annual Scientific Meeting of Hong Kong College of Radiologists, organised by Royal College of Radiologists and Hong Kong College of Radiologists at Hong Kong Academy of Medicine on 14th November 2015, Hong Kong.
16. **Lee V.H.F.** Advances of Radiation Therapy for Lung Cancer. Delivered in 2nd Hong Kong-Shenzhen International Cancer Congress, 第二届香港深圳國際腫瘤會議 organised by the University of Hong Kong-Shenzhen Hospital, Shenzhen, China on 21st November 2015.

17. **Lee V.H.F.** New Management Approach of EGFR TKI Resistance Progression. Delivered in the scientific symposium organized by Hong Kong Lung Cancer Study Group on 13th August 2016, Hong Kong.

(B) Local conferences (Total 36)

1. **Lee V.H.F.**, Brain tumour: presentation, investigation and management, In: Dr. Lee Ho Fun Victor, Hong Kong Anti-Cancer Society. 2008.
2. **Lee V.H.F.**, Brain Tumour: Presentation, Investigation and Management for the Elderly., Hong Kong Anti-Cancer Society in April 2009. Hong Kong, Hong Kong Anti-Cancer Society.
3. **Lee V.H.F.**, Brain Tumour: Presentation, Investigation and Management for the Elderly., Hong Kong Anti-Cancer Society on 26th October 2009, Hong Kong Anti-Cancer Society. 2009.
4. **Lee V.H.F.**, Management of Hand-foot Syndrome, Hong Kong Society of Clinical Oncology. 2010.
5. **Lee V.H.F.**, Management of nasopharyngeal carcinoma and other head and neck cancers, Institute of Advanced Nursing Studies, Hospital Authority. 2010.

6. **Lee V.H.F.**, Shifting the paradigm for maintenance therapy for non-small cell lung cancer, October 2010, Oncology Forum, Hong Kong College of Radiologists. 2010
7. **Lee V.H.F.**, Brain tumour: presentation, investigation and management, Hong Kong Anti-Cancer Society. Hong Kong, Hong Kong Anti-Cancer Society, 2010.
8. **Lee V.H.F.**, Management of nasopharyngeal carcinoma and its complications, Department of Speech Therapy, March 2011, Hong Kong East and Hong Kong West Clusters, Hospital Authority. 2011.
9. **Lee V.H.F.**, Management of Oesophageal and Gastric Cancer, June 2011, Department of Clinical Oncology, Queen Mary Hospital. 2011.
10. **Lee V.H.F.**, Going Through Lung Cancer, 21 August 2011, Queen Mary Hospital. 2011.
11. **Lee V.H.F.**, Targeted therapy for non-small cell lung cancer, Department of Clinical Oncology, Queen Mary Hospital. 2011.
12. **Lee V.H.F.**, Brain tumour: presentation, investigation and management, Hong Kong Anti-Cancer Society, 2011, Hong Kong Anti-cancer Society. 2011.
13. **Lee V.H.F.**, Comparative analysis of the efficacy of prophylactic pegfilgrastim versus filgrastim for patients with soft tissue sarcoma and testicular germ cell tumours receiving potent cytotoxic chemotherapy, October 2011, Proffered session, Annual Scientific Meeting 2011, Hong Kong College of Radiologists. Hong Kong, Hong Kong College of Radiologists, 2011.
14. **Lee V.H.F.**, Common Cancers in Hong Kong, 29 November 2011, University Health Service, The University of Hong Kong. Hong Kong, University Health Service, The University of Hong Kong, 2011.
15. **Lee V.H.F.**, Management of Early and Locally Advanced Lung Cancer, 2 April 2012, Multi-specialty Medical Mega Conference 2.0 by Association of Private Medical Specialists of Hong Kong. Hong Kong, Association of Private Medical Specialists of Hong Kong, 2012.
16. **Lee V.H.F.**, Medical management of brain tumors, May 2012, Institute of Advanced Nursing Studies, Hospital Authority. Hong Kong, Institute of Advanced Nursing Studies, Hospital Authority, 2012.
17. **Lee V.H.F.** and Chan Y.W., Chemoradiation for recurrent head and neck cancers in Head and Neck Course, Department of Surgery, The University of Hong Kong, Head and Neck Course, Department of Surgery, The University of Hong Kong. The University of Hong Kong, 2012.

18. **Lee V.H.F.**, Re-irradiation for laryngeal cancer, Head and Neck Course 2012, Department of Surgery, The University of Hong Kong. Hong Kong, Department of Surgery, The University of Hong Kong, 2012.
19. **Lee V.H.F.**, Personalized treatment for lung cancer at Lung Cancer Symposium, organised by Hong Kong College of Radiologists, Hong Kong College of Radiologists. Hong Kong, Hong Kong College of Radiologists, 2012.
20. **Lee V.H.F.**, New Ammunition for Lung Cancer, September 2012, Public Lecture Series 2012 - Li Ka Shing Faculty Medicine, The University of Hong Kong. Hong Kong, Li Ka Shing Faculty of Medicine, The University of Hong Kong, 2012.
21. **Lee V.H.F.**, Clinical Experience Sharing on the use of Anti-VEGF therapy for non-small cell lung cancer, September 2012, Roche Hong Kong Limited. Hong Kong, Roche Hong Kong Limited, 2012.
22. **Lee V.H.F.**, Nasopharyngeal Cancer: signs/ symptoms, investigation, treatment & prevention, October 2012, Hong Kong Anti-cancer Society. Hong Kong Anti-cancer Society, 2012.
23. **Lee V.H.F.**, Palliative radiotherapy for lung cancer, October 2012, Annual Scientific Meeting 2012, Hong Kong College of Radiologists. Hong Kong, Hong Kong College of Radiologists, 2012.
24. **Lee V.H.F.**, Common Cancers in Hong Kong – Diagnosis & Prevention, Health Education Programme by University Health Service, 2 December 2012, The University of Hong Kong. Hong Kong, University Health Service, The University of Hong Kong, 2012.
25. **Lee V.H.F.**, Management of Radiation-induced 2nd Head and Neck Malignancies from a Clinical Oncologist's Perspective, Hong Kong Head and Neck Society 21st Annual General Meeting and symposium on 11th April 2013. Hong Kong, Hong Kong Head and Neck Society.
26. **Lee V.H.F.**, Management of Lung Cancer, HKU Space. Hong Kong, SPACE, The University of Hong Kong, 2013.
27. **Lee V.H.F.**, Role of chemoradiation in cancer of the nasal cavity and paranasal sinuses, 06 June 2013, Head and Neck Course 2013, Department of Surgery, The University of Hong Kong. Hong Kong, Department of Surgery, The University of Hong Kong, 2013.
28. **Lee V.H.F.**, Adjuvant Therapy for Parotid Cancer, 30 September 2013, ENT course 2013 - Parotid, Palate & Paranasal Sinus Surgery. Hong Kong, Department of Surgery, The University of Hong Kong, 2013.

29. **Lee V.H.F.**, Case sharing on the use of cetuximab for oesophageal cancer, 14 September 2013, 2nd Oncology Summit. Merck Pharmaceutical (HK) Limited, 2013.
30. **Lee V.H.F.**, Nasopharyngeal Cancer: signs/ symptoms, investigation, treatment & prevention, 30 October 2013, Hong Kong, Hong Kong Anti-Cancer Society, 2013.
31. **Lee V.H.F.** Does Head and Neck Mucosal Melanoma Resembles the Cutaneous Type? Hong Kong Head and Neck Society Dinner Symposium, 16th October 2014, Hong Kong.
32. **Lee V.H.F.** Latest Research and Treatment Prospect of Lung Cancer. Delivered in Lung Cancer Symposium of Hong Kong Anti-Cancer Society, organised by Hong Kong Anti-Cancer Society, 24th October 2015, Hong Kong.
33. **Lee V.H.F.** Treatment Optimization with Ceritinib – Case Discussion”. Delivered in Novartis Lung Cancer Symposium, organised by Novartis Pharmaceuticals (HK) Ltd in Hong Kong on 17th March 2016.
34. **Lee V.H.F.** Optimizing treatment in ALK +ve non-small cell lung cancer. Delivered in the scientific symposium titled “scientific symposium “New Horizons Beyond Chemotherapy in Lung Cancer Treatments” organized by Hong Kong College of Radiologists at Hong Kong Academy of Medicine on 18 June 2016.
35. **Lee V.H.F.** Stereotactic radiosurgery and stereotactic body radiation therapy for brain and spinal metastases. Delivered in Neuroscience Working Group meeting on 23rd June 2016 organised by Department of Neurosurgery, Queen Mary Hospital, Hong Kong.
36. **Lee V.H.F.**, Nasopharyngeal Cancer: signs/ symptoms, investigation, treatment & prevention, 6th September 2016, Hong Kong, Hong Kong Anti-Cancer Society, 2016

(5) Prizes/Awards

1. Young Investigator Award In Psychosocial Oncology: Higher Education And Younger Age Are Associated With Better Understanding Of Clinical Trials Among Hong Kong Cancer Patients by 16th Hong Kong International Cancer Congress & 6th Annual Meeting Centre For Cancer Research in 2009 (co-investigator)
2. A Comparative Analysis of Homogeneity and Dose Distribution on Both Breasts Following Tangential Breast Irradiation with Field-in-field technique versus Conventional Technique with Two Wedge Filters for Early-staged Breast Cancer (principal investigator, shortlisted as one of the six finalists for the 2009 Prize for Best Original Research by Trainee held by the Hong Kong Academy of

Medicine)

3. IADR/SEA Joseph Lister Award for Oral Disease Prevention by International Association for Dental Research in 2013
4. Distinguished Young Fellow of Hong Kong Academy of Medicine in 2013
5. Hong Kong College of Radiologists HKCR 15A Travelling Fellowship in May 2014

Awards for My Postgraduate Students

1. HK\$ 21,050 was awarded to Miss Chen Leilei (as co-supervisor for PhD) under YS and Christabel Lung Postgraduate Scholarship, Li Ka Shing Faculty of Medicine, The University of Hong Kong in April 2010
2. Li Ka Shing Prize, Li Ka Shing Faculty of Medicine, The University of Hong Kong, was awarded to Miss Chen Leilei (as co-supervisor for PhD) for her best PhD thesis in 2010
3. RGC Postgraduate Students Conference Grants, The University of Hong Kong, awarded to Ms. Zhang Liyi (principal supervisor for PhD) for her poster presentation in 2012
4. RGC Postgraduate Students Conference Grants, The University of Hong Kong, awarded to Ms. Zhang Liyi (principal supervisor for PhD) for her poster presentation in 2013
5. YS and Christabel Lung Postgraduate Scholarship, The University of Hong Kong, awarded to Ms. Zhang Liyi (principal supervisor for PhD) in 2014
6. 2nd Runner-up, Scientific Imaging Competition, organised by Centre for Reproduction, Development and Growth, Li Ka Shing Faculty of Medicine, The University of Hong Kong, awarded to Ms. Fong Ho Lam (Principal supervisor for MPhil) in 2015

(6) Grant Records

(A) External peer-reviewed competitive research grants (Total 7 as PI and 14 as co-I)

Principal investigator

1. HK\$ 867,376 has been granted by Research Fund for the Control of Infectious Diseases, Food and Health Bureau, Hong Kong SAR Government (2011-2012) for the project titled "Host, Salivary, Virulent and Molecular Attributes to the Development of Oral Candidiasis During Intensity Modulated Radiation Therapy (IMRT) for Nasopharyngeal Carcinoma (NPC) – A Prospective Study" (**Principal investigator**). Period from 01 January 2012 to 31 December 2014.

Outcome - This project has completed successfully with 4 abstract publications. It will also be submitted to international peer-reviewed journal. The final report submitted to Food and Health Bureau on 30 December 2014 has been assessed and rated "4-Satisfactory" (please see the attached appendix)

2. HK\$ 1,087,376 has been granted by Health and Medical Research Fund, Food and Health Bureau, Hong Kong SAR Government (2015-2016) for the project titled "FDG and 11C-acetate PET-CT scan to assess tumour response after stereotactic body radiation therapy as bridging therapy for patients with hepatocellular carcinoma awaiting liver transplantation" (Project number 13142391) (**Principal**

investigator). Period from 31st May 2016 to 30th May 2019.

3. HK\$ 435,308 has been granted by Health and Medical Research Fund, Food and Health Bureau, Hong Kong SAR Government (2015-2016) for the project titled “Role of individual dietary counselling on weight loss and change in quality of life in patients with nasopharyngeal carcinoma treated with intensity-modulated radiation therapy” (Project number 03142346) (**Principal investigator**). Period from 31st May 2016 to 30th May 2018.

4. HK\$ 6,166,013 has been granted by Collaborative Research Fund, University Grants Committee, Hong Kong SAR Government (2015-2016) for the project titled “Efficient Algorithms and Hardware Accelerators for Tensor Decomposition and Their Applications to Multidimensional Data Analysis” (**Co-principal investigator**). Period from 1st June 2016 to 31st May 2019.

5. HK\$ 1,500,000 has been granted by Li Shu Pui Medical Foundation and Dean’s Fund for the project titled “Stereotactic body radiation therapy using cyberknife M6 radiosurgery system for locally advanced or inoperable and unresectable hepatocellular carcinoma” (**Principal investigator**). Period from 1st January 2018 to 31st December 2019.

6. HK\$ 1,194,778 has been granted by Health and Medical Research Fund, Food and Health Bureau, Hong Kong SAR Government (2017-2018) for the project titled “Territory-wide evaluation of treatment outcomes of non-metastatic nasopharyngeal carcinoma treated with radical intensity-modulated radiation therapy in Hong Kong” (Project number 15163081) (**Principal investigator**). Period from 1st May 2018 to 30th April 2021.

7. HK\$ 600,000 has been granted by General Research Fund, Research Grants Council, Hong Kong for the project titled “Tumour heterogeneity and clonal evolution in nasopharyngeal carcinoma” (Project number 17106718) (**Principal investigator**). Period 1st September 2018 to 31st August 2020.

Co-investigator

1. HK\$ 1,169,000 has been granted by General Research Fund (GRF), Research Grants Council, Hong Kong SAR Government for the project titled “PET/CT scan for early response monitoring and radiation dose escalation in locally advanced nasopharyngeal carcinoma” (Project number HKU 768312M) (**Co-investigator**). Period from 1st December 2012 to 30th November 2015. **Outcome-ongoing**

2. HK\$ 1,000,000 has been granted by Health and Medical Research Fund, Food and Health Bureau, Hong Kong SAR Government for the project titled “Identification of cancer metastasis and drug resistance pathways through comparison of primary and metastatic lung adenocarcinomas by next generation sequencing analysis” (Project number 01121306) (**Co-investigator**). Period from 01 April 2014 to 31 March 2016. **Outcome-ongoing**

3. HK\$ 989,030 has been granted by Health and Medical Research Fund, Food and Health Bureau, Hong Kong SAR government for the project titled “An assessor-blinded, randomised controlled trial of acupuncture to prevent chemobrain in breast cancer patients” (Project number 12133711) (**Co-investigator**). Period from 01 August 2015 till 31 July 2015. **Outcome-ongoing**
4. HK\$ 514,000 has been granted by General Research Fund (GRF), Research Grants Council, Hong Kong SAR Government for the project titled “Identification of at risk structures responsible for late dysphagia in nasopharyngeal carcinoma patients treated with radiotherapy” (Project number 17103215) (**Co-investigator**). Period from 1st January 2016 to 31st December 2017. **Outcome-ongoing**
5. HK\$ 800,008 has been granted by General Research Fund (GRF), Research Grants Council, Hong Kong SAR Government for the project titled “Speech and swallowing functions in 3 to 5 years post-treatment nasopharyngeal cancer survivors” (Project number 17606015) (**Co-investigator**). Period from 1st January 2016 to 31st December 2017. **Outcome-ongoing**
6. HK\$ 1,196,086 has been granted by Health and Medical Research Fund (HMRF), Food and Health Bureau, Hong Kong SAR government for the project titled “Translating intra-tumoural genetic heterogeneity to identify cancer progression genes in lung adenocarcinoma” (Project number 03142856) (**Co-investigator**). Period from 1st April 2016 to 30th September 2018. **Outcome-ongoing**
7. HK\$ 649,547 has been granted by General Research Fund (GRF), Research Grants Council, Hong Kong SAR Government for the project titled “Prospective study of stereotactic body radiation therapy as bridging therapy for hepatocellular carcinoma patients on waiting list for liver transplantation” (Project number 17149816) (**Co-investigator**). Period from 1st July 2016 to 30th June 2018. **Outcome-ongoing**
8. HK\$ 946,064 has been granted by Health and Medical Research Fund (HMRF), Food and Health Bureau, Hong Kong SAR government for the project titled “Optimizing the selection of patients with metastatic colorectal cancer for liver resection – An immuno-clinical scoring system incorporating circulating tumor cell enumeration and clinical factors” (Project number 04150726) (**Co-investigator**). Period from 1st May 2017 to 31st October 2019. **Outcome-ongoing**
9. HK\$ 1,125,384 has been granted by Health and Medical Research Fund (HMRF), Food and Health Bureau, Hong Kong SAR government for the project titled “Peripheral immunological response to treatment with checkpoint inhibitor in recurrent/metastatic nasopharyngeal carcinoma and correlation with clinical response and adverse effects” (Project number 05162186) (**Co-investigator**). Period from 6th September 2018 to 5th September 2020. **Outcome-ongoing**
10. HK\$ 99,627 has been granted by Health and Medical Research Fund (HMRF), Food and Health Bureau, Hong Kong SAR government for the project titled “Cost-effectiveness of anti-EGFR antibodies

as first-line treatment in RAS wild type (WT) metastatic colorectal cancer (mCRC) in Hong Kong” (Project number 15161781) (**Co-investigator**). Period from 1st April 2018 to 30th September 2018.

Outcome-ongoing

11. HK\$ 1,394,950 has been granted by Innovation and Technology Support Programme (Tier 3), Hong Kong SAR government for the project titled “Anticancer compounds from Chinese Medicine: Drug leads discovery, chemical modifications and formulations” (Project number ITS/345/16) (**Co-investigator**). Period from 1st September 2017 and 28th February 2019. **Outcome-ongoing**

12. HK\$ 906,100 has been granted by General Research Fund, Research Grants Council for the project titled “A multicenter, randomized controlled trial of stereotactic body radiation therapy (SBRT) versus transarterial chemoembolization (TACE) in patients with unresectable hepatocellular carcinoma”. (Project number 17115517) (**Co-investigator**). Period from to. **Outcome-ongoing**

13. HK\$ 845,825 has been granted by Health Care and Promotion Scheme, Research Grant Projects, Food and Health Bureau, Hong Kong SAR Government for the project titled “Disease awareness and oral health promotion for nasopharyngeal carcinoma (NPC) and head and neck radiotherapy survivors – a partnership model” (Project number 01170568) (**Co-investigator**). Period from 1st June 2018 to 31st January 2020. **Outcome-ongoing**

14. HK 1,121,020 has been granted by General Research Fund, Research Grants Committee, for the project titled “Pre-treatment and in-treatment swallowing therapy to reduce swallowing dysfunction in nasopharyngeal carcinoma patients treated with radiotherapy” (Project number 17107218) (**Co-investigator**). Period from 1st August 2018 to 31st July 2021. **Outcome-ongoing**

(B) External non-peer-reviewed competitive research grants (Total 5 as PI and 5 as co-I)

Principal Investigator

1. HK\$ 675,000 has been granted by SK Yee Medical Foundation (2010-2011) for the project titled “Complementary EBV testing for the poor and sick patients diagnosed to have nasopharyngeal carcinoma” (**Principal Investigator**). Period from 15 July 2010 to 14 July 2011. **Outcome-completed**

2. HK\$ 602,880 has been granted by SK Yee Medical Foundation (2012-2013) for the project titled “Complementary EBV DNA testing for the poor and sick patients diagnosed to have nasopharyngeal carcinoma” (**Principal Investigator**). Period from 1 January 2012 to 31 January 2013. **Outcome-completed**

3. HK\$ 577,202 has been granted by SK Yee Medical Foundation (2013-2014) for the project titled “Complimentary EBV DNA testing for the poor and sick patients diagnosed to have nasopharyngeal carcinoma” (**Principal Investigator**). Period from 1 January 2014 to 31 December 2014. **Outcome-completed**

4. HK\$ 570,100 has been granted by SK Yee Medical Foundation (2013-2014) for the project titled “Granulocyte-colony stimulating factor (G-CSF) support to prevent neutropenia and its complications for patients receiving palliative chemotherapy for their stage IV metastatic cancer”. (**Principal Investigator**). Period from 1 January 2014 to 31 December 2016. **Outcome-ongoing**

5. HK\$ 583,260 has been granted by SK Yee Medical Foundation (2014-2015) for the project titled “Magnetic resonance imaging (MRI) for monitoring treatment response in patients with inoperable hepatocellular carcinoma treated with transarterial chemoembolization (TACE) or radiotherapy”. (**Principal Investigator**). Period from 1 January 2015 to 30 March 2016. **Outcome-ongoing**

Co-investigator

1. HK\$ 677,500 has been granted by SK Yee Medical Foundation (2010-2011) for the project titled “Establishment of Personalized Therapy Regime for Advanced Non-small Cell Lung Cancer” (**Co-investigator**). Period from 01 September 2010 to 08 August 2011. **Outcome-completed**

2. HK\$ 677,700 has been granted by SK Yee Medical Foundation (2010-2011) for the project titled “Establishment of molecular tests for personalized therapy regime for lung cancer” (**Co-investigator**). Period from 01 September 2010 to 31 August 2012. **Outcome-completed**

3. HK\$ 150,000 has been granted by Bayer HealthCare Limited for the project titled “A retrospective study of systemic therapy in metastatic colorectal cancer in Queen Mary Hospital” (**Co-investigator**). Period from 01 January 2015 till 31 December 2015. **Outcome-ongoing**

4. HK\$ 50,000 has been granted by Taiho Pharma Ltd for the project titled “Feasibility study of intraperitoneal docetaxel combined with intravenous cisplatin and oral TS-ONE for gastric cancer patients with peritoneal carcinomatosis” (**Co-investigator**). Period from 01 July 2013 till 25 December 2015. **Outcome-ongoing**

5. HK\$ 231,504 has been granted by SK Yee Medical Foundation for the project titled “Improving Access to Chemotherapy in Locoregionally Advanced Esophageal and Rectal Cancer for the Poor and Sick” (**Co-investigator**). Period from 1st March 2016 to 28th February 2017. **Outcome-ongoing**

(C) Internal grants (Total 7 as PI and 8 as co-I)

Principal investigator

1. HK\$ 120,000 has been granted by Seeding Funding Programme for Basic Research, The University of Hong Kong (Reference number 200811159020) for the project titled “A retrospective analysis of genetic aberrations as predictors of relapse and survival outcomes in completed resected stage III adenocarcinoma of colon after the use of oxaliplatin-based regimens as adjuvant chemotherapy” (**Principal Investigator**). Period from 01 March 2009 to 28 February 2011. **Outcome-completed**

2. HK\$ 16,500 granted by URC/CRCG – Conference Grants for Teaching Staff, The University of Hong Kong (Reference number 200807170500), for the 51st American Society For Radiation Oncology (ASTRO) Annual Meeting 2009 (**Principal Investigator**). Period from 01 November 2009 to 05 November 2009. **Outcome-completed**

3. HK\$ 100,000 has been granted by Teaching Development Grant, The University of Hong Kong for Common Core Curriculum (2010-2011) for the course titled “Science and Health: the ever-changing challenges and solutions” (**Principal Investigator**). Period from 01 July 2010 to 30 June 2011. **Outcome-completed**

4. HK\$ 190,000 per year for a total of 6 years granted by the Common Core Curriculum Committee, The University of Hong Kong for the common core course titled “Science and Health: the ever-changing challenges and solutions” (**Principal Investigator and Course Coordinator**). Period from 01 July 2010 to 30 June 2015. **Outcome-completed**

5. HK\$ 56,547 has been granted by Small Project Funding, RGC Direct Allocation of the University of Hong Kong for the project titled “A prospective study on the anatomical and physiological changes of carotid arteries by doppler ultrasonography after Intensity Modulated Radiation Therapy (IMRT) for untreated nasopharyngeal carcinoma (NPC)” (**Principal Investigator**). Period from 01 July 2011 to 30 Jun 2011. **Outcome-completed**

6. HK\$ 69,575 has been granted by Small Project Funding RGC Direct Allocation of the University of Hong Kong for the project titled “Identification of epithelial stem cells and factors predicting recovery of mucositis after intensity modulated radiation therapy (IMRT) for patients with nasopharyngeal carcinoma (NPC)” (**Principal Investigator**). Period from 30 June 2014 to 31 March 2016. **Outcome-ongoing**

7. HK\$ 15,236 has been granted by URC/CRCG - Conference Support for Teaching Staff, The University of Hong Kong. ASTRO 56th Annual Meeting; Comparison of Post-treatment Plasma EBV DNA with Nasopharyngeal Biopsy in Patients After Radical (Chemo)Radiotherapy for Non-metastatic Nasopharyngeal Cancer. Period from 14 September 2014 to 17 September 2014. **Outcome-completed**

Co-Investigator

1. HK\$ 120,000 has been granted by Seed Funding Programme for Basic Research, The University of Hong Kong (Reference number 20104159004) for the project titled “Comparison of DWIBS MRI and PETCT for the diagnostic performance and the accuracy of treatment response monitoring in GISTs” (**Co-investigator**). Period from 01 June 2010 to 31 May 2012. **Outcome-completed**

2. HK\$ 120,000 has been granted by Seed Funding Programme for Basic Research, The University of

Hong Kong for the project titled “A prospective study on the predictive and prognostic value of baseline biomarker expressions in locally advanced rectal cancer treated with neoadjuvant chemoradiation using capecitabine” (**Co-investigator**). Period from 17 January 2012 to 16 July 2014. **Outcome-completed**

3. HK\$ 36,800 has been granted by Small Project Funding, The University of Hong Kong (Reference number 201109176124) for the project titled “Genetic causes of tyrosine kinase inhibitor resistance in advanced lung cancer patients” (**Co-investigator**). Period from 01 May 2012 to 30 April 2013.

Outcome-completed

4. HK\$ 120,000 has been granted by Seeding funding Programme for Basic Research, The University of Hong Kong (Reference number 201308159002) for the project titled “Feasibility and prognostic impact of DNA repair gene profiling by PCR array in locally advanced nasopharyngeal carcinoma treated with radiotherapy alone or in conjunction with chemoradiotherapy” (**Co-investigator**). Period from 01 November 2013 to 31 July 2014. **Outcome-completed**

5. HK\$ 59,900 has been granted by Seed Funding Programme for Basic Research, The University of Hong Kong (Reference number 201311159014) for the project titled “Impact of intensity-modulated radiotherapy on head and neck cancer survivors' long-term swallowing functions” (**Co-investigator**). Period from 30 June 2014 to 29 June 2016. **Outcome-going**

6. HK\$ 64,024 has been granted by Small Project Funding, The University of Hong Kong for the project titled “PD-L1 immunohistochemical expression in esophageal cancers” (**Co-investigator**). Period from 01 April 2015 to 30 Sep 2016. **Outcome-ongoing**

7. HK\$ 117,402 has been granted by Seed Funding Programme for Basic Research, The University of Hong Kong for the project titled “A randomised controlled trial of acupuncture for oxaliplatin-based chemotherapy-induced peripheral neuropathy (CIPN) in colorectal cancer patients” (**Co-investigator**). Period from 30th June 2015 to 29th June 2016. **Outcome-ongoing**

8. HK\$ 150,000 has been granted by Seed Funding Programme for Basic Research, The University of Hong Kong for the project titled “Prognostic and predictive biomarkers in loco-regionally advanced nasopharyngeal carcinoma treated with radiotherapy alone or in conjunction with chemotherapy: pooled analysis of data from the NPC-9901 and NPC-9902 trials” (Co-investigator). Period from 14th April 2016 to 13th April 2018. **Outcome-ongoing**

(7) Knowledge exchange

1. Lee V.H.F.. Delivery of a Public Lecture on “New Ammunition for Lung Cancer” “治療肺癌新契機” organized by Public Lecture Series 2012, Li Ka Shing Faculty of Medicine, The University of Hong Kong.

2. **Lee V.H.F.** Published a book chapter on “New Ammunition for Lung Cancer” “治療肺癌新契機” of Public Lecture Booklet (English and Chinese) in 2014 by Li Ka Shing Faculty of Medicine, The University of Hong Kong.
3. **Lee V.H.F.** Published a book chapter on “Prevention and Management of Colorectal Cancer” “大腸癌治療與預防” 3rd Edition in 2011 and 4th Edition in 2014 by Hong Kong Anti-Cancer Society
4. **Lee V.H.F.** 李浩勳醫生 Book chapter on Radiation Therapy for Colorectal Cancer in “Education book on Colorectal Cancer”, published by Hong Kong Anti-Cancer Society in 2011
5. **Lee V.H.F.** 李浩勳醫生 Book chapter on “免疫營養與口腔黏膜炎” in 有營同路人 by 紅出版 (青森文化) in 2016

(8) Supervision of post-graduate students

1. Principal supervisor of Dr. Fang Weijia (Dr. Cheng Yu Tung Fellowships 2011-2012 Visiting Fellow, The University of Hong Kong), Department of Medical Oncology, First Affiliated Hospital, Zhejiang University, People's Republic of China) (Completed in 2011)
2. Principal supervisor of Miss Zhang Liyi, Department of Clinical Oncology, The University of Hong Kong (graduated and conferred for PhD in 2015)
3. Principal supervisor of Mr. Liu Wai Man for PhD, Department of Clinical Oncology, The University of Hong Kong (graduated and conferred for PhD in 2017)
4. Principal supervisor of Ms. Fong Ho Lam for MPhil, Department of Clinical Oncology, The University of Hong Kong (graduated and conferred for MPhil in 2017)
5. Principal supervisor of Mr. Lam Wai Wang Tomie for MPhil, Department of Clinical Oncology, The University of Hong Kong (ongoing without delay)
6. Co-supervisor of Mr. Yu Zhuoyou for PhD, Department of Clinical Oncology (graduated and conferred for PhD in 2014), The University of Hong Kong (graduated and conferred for PhD in 2014)
7. Co-supervisor of Miss Chen Leilei for PhD, Department of Clinical Oncology, The University of Hong Kong (graduated and conferred for PhD in 2012)
8. Co-supervisor of Miss Zhu Cailei for PhD, Department of Clinical Oncology, The University of Hong Kong (graduated and conferred for PhD in 2011)
9. Co-supervisor of Ms. Choy Shan Shan for PhD, Department of Clinical Oncology, The University of Hong Kong (ongoing without delay)
10. Principal supervisor of Ms. He Jiaozi for PhD, Department of Clinical Oncology, The University of Hong Kong (ongoing without delay)
11. Principal supervisor of Dr. Liu Huai (Dr. Cheng Yu Tung Fellowships 2017-2018 Clinical Visiting Fellow, The University of Hong Kong), Department of Radiation Oncology, ChangSha Oncology Hospital, Changsha, Hunan, China (Completed in January 2018)

(9) Examiner of post-graduate students

1. Miss Fung Wing Ki, MPhil, Department of Health Technology and Informatics, The Hong Kong

- Polytechnic University, 2012 (External examiner)
2. Miss Chui Tung Yung, MMedSc, Department of Pathology, The University of Hong Kong, 2013 (Internal examiner)
 3. Mr. Ting Kam Po, MPhil, Department of Pathology, The University of Hong Kong, 2009 (Internal examiner)
 4. Miss Choi Kit Chi, Gigi, MMedSci, Department of Pathology, The University of Hong Kong, 2011 (Internal examiner)
 5. Mr. Wong Ka Wai, MPhil, Department of Clinical Oncology, The University of Hong Kong, 2011 (Internal examiner)
 6. Mr. Huang Bingsheng, PhD, Department of Diagnostic Radiology, The University of Hong Kong, 2012 (Internal examiner)
 7. Mr. Zheng Chunyan, PhD, Department of Medicine, The University of Hong Kong, 2014 (Internal examiner)
 8. Ms. Han Li, PhD, Department of Medicine, The University of Hong Kong, 2016 (Internal examiner)
 9. Mr. Lo Chi Shing, Department of Microbiology, The University of Hong Kong, 2017 (Internal examiner)
 10. Mr. Liu Cheuk Him, MMedSci, Department of Clinical Oncology, The University of Hong Kong, 2017 (Internal examiner)
 11. Mr. Faisal Nouman BAIG, PhD, Department of Health Technology and Informatics, The Hong Kong Polytechnic University, 2017 (External examiner)

(10) Other supervision of post-graduate students

1. Tutor of junior staff for the Fellowship of Royal College of Radiologists Final Examination in Clinical Oncology since 2011
2. Tutor of junior staff for the Fellowship of Royal College of Radiologists Final Examination in Clinical Oncology since 2015

(11) Editor of Journal

1. Modern Chemotherapy, from Jan 2013 to December 2015, USA
2. Associate Editor, Clinical Oncology (Royal College of Radiologists), from July 2017 till now, The United Kingdom

(12) Reviewer of Journals

1. Journal of Clinical Oncology (Impact factor: 20.982; 5-year impact factor: 18.021)
2. International Journal of Cancer (Impact factor: 6.513; 5-year impact factor: 5.085)
3. Journal of Nuclear Medicine (Impact factor: 5.849; 5-year impact factor: 5.795)
4. Journal of Thoracic Oncology (Impact factor: 5.040; 5-year impact factor: 4.932)

5. Oncotarget (Impact factor: 5.008; 5-year impact factor: 5.415)
6. International Journal of Radiation Oncology Biology Physics (Impact factor: 4.495; 5-year impact factor: 4.379)
7. Lung Cancer (Impact factor: 3.767; 5-year impact factor: 3.760)
8. Targeted Oncology (Impact factor: 3.197; 5-year impact factor: 3.019)
9. PLoS One (Impact factor: 3.057; 5-year impact factor: 3.535)
10. Chinese Journal of Cancer (Impact factor: 2.814; 5-year impact factor: 0)
11. Head and Neck (Impact factor: 2.760; 5-year impact factor: 2.790)
12. Oncotargets and Therapy (Impact factor: 2.272; 5-year impact factor: 2.235)
13. Asia-Pacific Journal of Clinical Oncology (Impact factor: 1.722; 5-year impact factor: 1.472)
14. World Journal of Surgical Oncology (Impact factor: 1.286; 5-year impact factor: 1.458)
15. Hong Kong Medical Journal (Impact factor: 0.887; 5-year impact factor: 0)
16. Journal of Medical Case Reports (Impact factor: 0; 5-year impact factor: 0)
17. Hong Kong Journal of Radiology (Impact factor: 0; 5-year impact factor: 0)
18. Modern Chemotherapy (Impact factor: 0; 5-year impact factor: 0)
19. Practical Radiation Oncology (Impact factor: 0; 5-year impact factor: 0)
20. Journal of Clinical Medicine (Impact factor: 0; 5-year impact factor: 0)

(13) External Grant Reviewer

Reviewer of external grant of Hong Kong Baptist University

(14) Administration

1. Participation into the departmental and hospital accreditation by The Australian Council on Healthcare Standards ACHS in 2010 by preparation of management guidelines on non-small cell lung cancer and lung cancer with updates in 2012 and 2014
2. Chief author of departmental guidelines on “Management of non-small cell lung cancer” and “Management of small-cell lung cancer” for hospital accreditation by The Australian Council on Healthcare Standards ACHS in 2010 with updates in 2012 and 2014.
3. Co-author of departmental guidelines on “Management of Nasopharyngeal Cancer” for hospital accreditation by The Australian Council on Healthcare Standards ACHS in 2014
4. Production of management guidelines on stereotactic radiosurgery for brain tumors for Central Organising Committee (COC), Clinical Oncology, Hospital Authority in 2013
5. Departmental coordinator for the successful application as an affiliate member of Radiation Therapy Oncology Group (RTOG) in 2013

Teaching and Learning

1. Course Coordinator of Common Core Course “CCST9005 – Science and Health: The Ever-changing Challenges and Solutions” of 4-year Common Core Curriculum, The University of Hong Kong from 2010 till now

Our course has been awarded Teaching Development Grant (TDG) for Common Core Course in 2010. I am responsible for design of course curriculum, course pedagogy, contents, student assignments, etc. Our course is one of the founding courses since the inception of Common Core Curriculum in 2010, and one of the founding courses incorporating Problem-Based Learning (PBL) in small-group tutorials. We submitted an abstract on our teaching pedagogy to the 5th International Conference of Education, Research and Innovation, held in Germany in 2012 and the abstract was accepted as poster presentation. Our teaching portfolio is attached here for reference. Our course is well-appraised with high scores in Student Evaluation on Teaching and Learning (SETL). Our team has also submitted the application for Teaching Excellence Award of the University of Hong Kong in 2014.

2. I am actively engaged in teaching for our MBBS III and IV students with high SETL scores as compared to other departmental colleagues. Besides, I am currently part-time lecturer for students of Department of Health Technology and Informatics at Hong Kong Polytechnic University. In addition, I am tutor of candidates for Final Examination for the Fellowship of Royal College of Radiologists since 2010.
3. I am holding numerous faculty and departmental positions for MBBS students including (1) MBBS Year 3 Block C Deputy Coordinator, (2) MBBS Year 3 Deputy Assessment Coordinator, (3) MBBS Year 3 Block C Departmental Coordinator, (4) MBBS Year 3 (6-year) Deputy Assessment Coordinator (Written and OSCA), member of the Institute of Medical and Health Sciences Education (IMHSE), and member of the Task Force on Head and Neck Block and Mechanisms of Disease Block.

Post-graduate supervision

I am principal supervisor of 2 PhD students and 1 MPhil student. 1 PhD student has graduated in 2014 with PhD conferment of PhD and she was awarded YS and Christabel Lung Postgraduate Scholarship in 2014. The studies of the other PhD and MPhil students are ongoing without delay. I am also principal supervisor of Dr. Fang Weijia for his Dr. Cheng Yu Tung Fellowships as Visiting Fellow in 2011 to 2012. I have also been co-supervisors of 4 other PhD and MPhil students.

Services

1. I am holding numerous faculty and departmental positions for the enhancement of teaching for MBBS students since 2009
2. Honorary secretary, president-elect, president of Hong Kong Head and Neck Society since 2010 till now
3. Member, Central Committee (genetic services), Hospital Authority, Hong Kong since 2010
4. Member of Education and Research Fund Subcommittee, Hong Kong College of Radiologists since 2012
5. I am serving as Education Subcommittee member of Hong Kong Anti-Cancer Society since 2014
6. I am also serving as honorary consultant of Kin Lok Club (a local community patient group on nasopharyngeal carcinoma)

1st March 2018